GPR35 modulators

By regulating GPR35 receptor activity, the use of compounds formula (I), (I') or (I") to treat inflammatory bowel disease, solves the problem of insufficient response to IBD patients with existing treatments, providing targeted and effective Treatment plan.

CN113631168BActive Publication Date: 2024-11-19PROMETHEUS BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080024043.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-10-30
Filing Date
2020-01-23
Publication Date
2024-11-19
Estimated Expiration
2040-01-23

AI Technical Summary

Technical Problem

The existing IBD treatment methods are inadequate in response to patients with inflammatory bowel disease, especially the high resistance to anti-TNF treatment, which leads to disease progression and lacks targeted and effective treatment options.

Method used

Provided is a compound of formula (I), (I') or (I") and a pharmaceutically acceptable salt or solvate thereof for modulating the GPR35 receptor for the treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Benefits of technology

By modulating GPR35 activity, a novel therapeutic option for inflammatory bowel disease is provided, which may improve treatment responsiveness and alleviate disease symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003276832660000021
    Figure BDA0003276832660000021
  • Figure BDA0003276832660000041
    Figure BDA0003276832660000041
  • Figure BDA0003276832660000071
    Figure BDA0003276832660000071
Patent Text Reader

Abstract

Described herein are GPR35 modulators and methods of using these compounds to treat diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 796,459, filed January 24, 2019, U.S. Provisional Application No. 62 / 873,703, filed July 12, 2019, and U.S. Provisional Application No. 62 / 928,223, filed October 30, 2019, all of which are incorporated herein by reference in their entirety. Background Art

[0003] Millions of people are affected by inflammatory diseases or conditions. One important inflammatory disease is inflammatory bowel disease (IBD). IBD has two common forms—Crohn's disease (CD) and ulcerative colitis (UC), which are chronic, relapsing inflammatory conditions of the gastrointestinal tract. Each of these forms has a variety of sub-conditions that exist in subsets of CD and UC patients. Some CD and UC patients experience a rapid onset of a sub-condition, while others experience a more delayed onset.

[0004] Patients with IBD have almost no available treatment options. In addition, due to the unpredictability of each individual's prognosis, it is complicated to select a therapy that is suitable for any individual patient at any given stage of the disease. Current treatment options include one or more anti-inflammatory drugs (such as corticosteroids) and immunomodulatory therapies (such as anti-TNF therapies). However, nearly half of the patients receiving anti-TNF therapy do not respond to the induction of treatment or lose their response to treatment after a period of time, during which time the severity of the disease progresses significantly. Therefore, there is still a great need for targeted and effective treatment options that respond to the underlying immune pathogenesis of IBD. Summary of the Invention

[0005] In one aspect, provided herein are compounds of formula (I"):

[0006]

[0007] in:

[0008] R 1 -CH2R 4 、-CN、-B(OH)2、-N(R 10 )2、-NR 10 C(O)R 9 , -C(O)OH, -CH2C(O)OH, -C(O)N(R 10 )2、-C(O)NHS(O)2N(R 10 )2. -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl, or optionally one, two or three R 8 A 5- or 6-membered heteroaryl group substituted with a group;

[0009] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)N(R 10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0010] Each R 3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-NO2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C1-6 Alkyl-C 3-8 Cycloalkyl;

[0011] R 4 for

[0012] Each R 5 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-R 9 、-C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 2-6 Alkenyl, -C 2-6 Alkenyl-C(O)OR 10 、C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein C 3-8Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, -C(O)OR 10 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl and -C 1-6 Alkyl-C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, -C(O)OR 10 、C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0013] R 6 -C(O)OR 7 、-C(O)NHS(O)2N(R 10 )2.

[0014] R 7 Independently selected from H and C 1-6 alkyl;

[0015] Each R 8 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0016] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR 11 、-N(R 11 )2、C 1-6 Alkyl, C 3-8 Cycloalkyl, -N(R 11)C(O)R 12 、-C(O)R 12 and -C(O)OR 12 substituted by a group;

[0017] Each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0018] Each R 11 Independently selected from H and C 1-6 alkyl;

[0019] Each R 12 Independently selected from H and C 1-6 alkyl;

[0020] Each R 13 Independently selected from C 1-6 alkyl;

[0021] m is 1, 2, 3 or 4;

[0022] n is 0, 1, 2, or 3;

[0023] p is 0, 1, 2, 3, 4 or 5; and

[0024] q is 0, 1, 2, 3, or 4;

[0025] or a pharmaceutically acceptable salt or solvate thereof.

[0026] In another aspect, provided herein is a compound of formula (I'):

[0027]

[0028] in:

[0029] R 1 -CH2R 4 、-CN、-B(OH)2、-N(R 10 )2、-NR 10 C(O)R 9 , -C(O)OH, -CH2C(O)OH, -C(O)N(R 10 )2、-C(O)NHS(O)2N(R 10 )2. -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl, or optionally one, two or three R 8 A 5- or 6-membered heteroaryl group substituted with a group;

[0030] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)N(R 10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0031] Each R 3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 Cycloalkyl;

[0032] R 4 for

[0033] Each R 5 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-R 9 、-C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 2-6 Alkenyl, -C 2-6 Alkenyl-C(O)OR10 、C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0034] R 6 -C(O)OR 7 、-C(O)NHS(O)2N(R 10 )2.

[0035] Each R 7 Independently selected from H and C 1-6 alkyl;

[0036] Each R 8 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0037] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR 11、-N(R 11 )2、C 1-6 Alkyl, C 3-8 Cycloalkyl, -N(R 11 )C(O)R 12 、-C(O)R 12 and -C(O)OR 12 substituted by a group;

[0038] Each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0039] Each R 11 Independently selected from H and C 1-6 alkyl;

[0040] R 12 Independently selected from H and C 1-6 alkyl;

[0041] n is 0, 1, 2, or 3;

[0042] p is 0, 1, 2, 3, 4, or 5;

[0043] q is 0, 1, 2, 3, or 4;

[0044] or a pharmaceutically acceptable salt or solvate thereof.

[0045] In another aspect, provided herein are compounds of formula (I):

[0046]

[0047] in:

[0048] R 1 -CH2R4 、-CN、-B(OH)2、-N(R 10 )2、-NR 10 C(O)R 9 , -C(O)OH, -CH2C(O)OH, -C(O)N(R 10 )2、-C(O)NHS(O)2N(R 10 )2. -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl, or optionally one, two or three R 8 A 5- or 6-membered heteroaryl group substituted with a group;

[0049] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)N(R 10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0050] Each R 3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 Cycloalkyl;

[0051] R 4 for

[0052] Each R 5 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0053] R 6 -C(O)OR 7 、-C(O)NHS(O)2N(R 10 )2.

[0054] Each R 7 Independently selected from H and C 1-6 alkyl;

[0055] Each R 8 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0056] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR 11 、-N(R 11 )2、C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 and -C(O)OR 12 substituted by a group;

[0057] Each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0058] Each R 11 Independently selected from H and C 1-6 alkyl;

[0059] R 12 Independently selected from H and C 1-6 alkyl;

[0060] n is 0, 1, 2, or 3;

[0061] p is 0, 1, 2, 3, 4, or 5;

[0062] q is 0, 1, 2, 3, or 4;

[0063] or a pharmaceutically acceptable salt or solvate thereof.

[0064] In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for In some embodiments, the compound is a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0, 1 or 2. In some embodiments, the compound is a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl and C 1-9 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and C 1-9 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 5 Independently selected from -OR 9 、-C(O)OR 10 、-C(O)N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 5 Independently selected from -C(O)OR 10 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 5 Independently selected from -OH, -OR 9 and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 9 is optionally -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 Independently selected from H and C 1-6 Alkyl. In some embodiments, the compound is a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2. In some embodiments, the compound is a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1. In some embodiments, the compound is a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 2. In some embodiments, the compound is a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0. In some embodiments, the compound is a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound is a compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound is a compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8substituted 5-membered heteroaryl, wherein the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl and thiadiazolyl. In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 substituted 5-membered heteroaryl, wherein the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl and isoxazolyl. In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound is a compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound is a compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound is a compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8 independently selected from halogen, -C(O)OR 10 、C 1-6 Alkyl and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, each R 8 Independently selected from -C(O)OR 10 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl and isoxazolyl. In some embodiments, it is a compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1is an unsubstituted 6-membered heteroaryl selected from pyridinyl and pyrimidinyl. In some embodiments, it is a compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2. In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2. In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound is of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 Independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound is of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 independently selected from H and optionally substituted by -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein the two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein the two R 10 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein the two R 10 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 H, -OH, -N(R 10 )2 or -OC 1-6 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For-OC 1-6 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments, it is a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, it is a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 3 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 and C 1-6 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 3independently selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 3 For-OR 9 And R 9 C 3-8 In some embodiments, the compound of formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0065] In another aspect, described herein is a pharmaceutical composition comprising a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0066] In another aspect, described herein is a method of treating an inflammatory bowel disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating an inflammatory bowel disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I') or (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein the inflammatory bowel disease is selected from Crohn's disease, ulcerative colitis, and perianal Crohn's disease. In some instances, the ulcerative colitis is a severe form of ulcerative colitis. In some instances, the severe form of ulcerative colitis is medically refractory ulcerative colitis.

[0067] In another aspect, described herein is a method of modulating GPR35 activity comprising contacting GPR35, or a portion thereof, with a compound of Formula (I), (I'), or (I"), or a pharmaceutically acceptable salt or solvate thereof.

[0068] Incorporation by reference

[0069] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION

[0070] definition

[0071] In the context of this disclosure, a number of terms will be used.

[0072] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as generally understood in the art to which the claimed subject matter belongs. Where a term has multiple definitions herein, the definitions in this section shall prevail. All patents, patent applications, publications, and disclosed nucleotide and amino acid sequences (e.g., sequences available from GenBank or other databases) cited herein are incorporated by reference. When a URL or other such identifier or address is referenced, it is understood that such identifiers may change, and that specific information on the Internet may be fleeting, but equivalent information can be found by searching the Internet. Reference thereto demonstrates the availability and public release of such information.

[0073] It should be understood that the foregoing general description and the following detailed description are exemplary and illustrative only and are not limitations on any subject matter claimed. In this application, unless otherwise specifically stated, the use of the singular includes the plural. It must be noted that the singular forms "a", "an", and "the" used in this specification and the appended claims include plural referents unless the context clearly indicates otherwise. In this application, the use of "or" means "and / or" unless otherwise stated. In addition, the use of the term "includes" and other forms such as "comprises", "contains", and "has" is not restrictive.

[0074] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0075] Definitions of standard chemical terms may be found in references including, but not limited to, Carey and Sundberg "Advanced Organic Chemistry 4th Edition," Volumes A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques, and pharmacology are employed.

[0076] Unless specifically defined, the nomenclature and laboratory procedures and techniques used for analytical chemistry, synthetic organic chemistry, medicine and pharmaceutical chemistry as described herein are generally recognized in the art. Standard techniques can be used for chemical synthesis, chemical analysis, drug preparation, formulation and delivery and treatment of patients. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis and tissue culture and transformation (e.g., electroporation, lipofection). For example, reactions and purification techniques can be performed using a kit of manufacturer's specifications, or in a manner commonly achieved in the art, or as described herein. The aforementioned techniques and procedures can be performed conventionally and as described in the various general and more specific references cited and discussed throughout this specification.

[0077] It should be understood that the methods and compositions described herein are not limited to the specific methods, protocols, cell lines, constructs and reagents described herein, and therefore these may vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the methods, compounds, and compositions described herein.

[0078] As used herein, C1-Cx includes C1-C2, C1-C3, ... C1-Cx. C1-Cx refers to the number of carbon atoms (excluding optional substituents) that constitute the moiety to which it refers.

[0079] An "alkyl" group refers to an aliphatic hydrocarbon group. An alkyl group may or may not include unsaturated units. An alkyl moiety may be a "saturated alkyl" group, meaning that it does not contain any unsaturated units (i.e., carbon-carbon double bonds or carbon-carbon triple bonds). An alkyl group may also be an "unsaturated alkyl" moiety, meaning that it contains at least one unsaturated unit. An alkyl moiety, whether saturated or unsaturated, may be branched, straight chain, or cyclic.

[0080] An "alkyl" group can have from 1 to 6 carbon atoms (whenever it appears herein, a numerical range such as "1 to 6" refers to each integer in the given range; for example, "1 to 6 carbon atoms" means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 6 carbon atoms, although the present definition also encompasses the presence of the term "alkyl" without specifying a numerical range). The alkyl group of the compounds described herein can be designated as "C1-C6 alkyl" or similar designations. By way of example only, "C1-C6 alkyl" means that there are from one to six carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, propen-3-yl (allyl), cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl. Alkyl groups can be substituted or unsubstituted. Depending on the structure, an alkyl group can be monovalent or divalent (i.e., an alkylene group).

[0081] "Alkoxy" refers to an "-O-alkyl" group where alkyl is as defined herein.

[0082] The term "alkenyl" refers to a type of alkyl group in which the first two atoms of the alkyl group form a double bond that is not part of an aromatic group. That is, an alkenyl group begins with the atom -C(R)=CR2, where R refers to the rest of the alkenyl group, which may be the same or different. Non-limiting examples of alkenyl groups include -CH=CH2, -C(CH3)=CH2, -CH=CHCH3, -CH=C(CH3)2, and -C(CH3)=CHCH3. The alkenyl portion may be branched, straight-chain, or cyclic (in which case it is also referred to as a "cycloalkenyl" group). An alkenyl group may have 2 to 6 carbons. An alkenyl group may be substituted or unsubstituted. Depending on the structure, an alkenyl group may be monovalent or divalent (i.e., an alkenylene group).

[0083] The term "alkynyl" refers to a type of alkyl group in which the first two atoms of the alkyl group form a triple bond. That is, an alkynyl group begins with the atom -C≡CR, where R refers to the remainder of the alkynyl group. Non-limiting examples of alkynyl groups include -C≡CH, -C≡CCH3, -C≡CCH2CH3, and -C≡CCH2CH2CH3. The "R" portion of the alkynyl moiety can be branched, straight-chain, or cyclic. An alkynyl group can have 2 to 6 carbon atoms. An alkynyl group can be substituted or unsubstituted. Depending on the structure, an alkynyl group can be monovalent or divalent (i.e., an alkynylene group).

[0084] "Amino" refers to a -NH2 group.

[0085] The term "alkylamine" or "alkylamino" refers to an -N(alkyl)xHy group, where alkyl is as defined herein, and x and y are selected from the group consisting of x=1, y=1 and x=2, y=0. When x=2, the alkyl groups, together with the nitrogen to which they are attached, may optionally form a cyclic ring system. "Dialkylamino" refers to an -N(alkyl)2 group, where alkyl is as defined herein.

[0086] The term "aromatic" refers to a planar ring having a delocalized π-electron system containing 4n+2 π electrons, where n is an integer. An aromatic ring can be formed by five, six, seven, eight, nine, or more than nine atoms. Aromatic groups can be optionally substituted. The term "aromatic" includes both aryl groups (e.g., phenyl, naphthyl) and heteroaryl groups (e.g., pyridyl, quinolinyl).

[0087] As used herein, the term "aryl" refers to an aromatic ring in which each atom forming the ring is a carbon atom. An aryl group can be formed by five, six, seven, eight, nine, or more than nine carbon atoms. An aryl group can be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl and naphthyl. Depending on the structure, an aryl group can be monovalent or divalent (i.e., an arylene group).

[0088] "Carboxyl" refers to -CO2H. In some embodiments, the carboxyl moiety can be replaced by a "carboxylic acid bioisostere," which refers to a functional group or moiety that exhibits similar physical and / or chemical properties as a carboxylic acid moiety. Carboxylic acid bioisosteres have similar biological properties as carboxylic acid groups. The carboxylic acid moiety of a compound having a carboxylic acid moiety is interchangeable with a carboxylic acid bioisostere, and it has similar physical and / or biological properties compared to the carboxylic acid-containing compound. For example, in one embodiment, a carboxylic acid bioisostere will ionize at physiological pH to approximately the same extent as a carboxylic acid group. Examples of bioisosteres of carboxylic acids include, but are not limited to wait.

[0089] The term "cycloalkyl" refers to a monocyclic or polycyclic non-aromatic group in which each atom comprising the ring (i.e., backbone atoms) is a carbon atom. A cycloalkyl group may be saturated or partially unsaturated. A cycloalkyl group may be fused to an aromatic ring (in which case the cycloalkyl group is bonded via a non-aromatic ring carbon atom). Cycloalkyl groups include groups having from 3 to 10 ring atoms.

[0090] The term "heteroaryl" or alternatively "heteroaromatic" refers to an aromatic group that includes one or more ring heteroatoms selected from nitrogen, oxygen, and sulfur. An N-containing "heteroaromatic" or "heteroaryl" moiety refers to an aromatic group in which at least one skeletal atom of the ring is a nitrogen atom.

[0091] A "heterocycloalkyl" or "heteroalicyclic" group refers to a cycloalkyl group in which at least one backbone ring atom is a heteroatom selected from nitrogen, oxygen, and sulfur. This group may be fused to an aryl or heteroaryl group. The term heteroalicyclic also includes all cyclic carbohydrates, including but not limited to monosaccharides, disaccharides, and oligosaccharides. Unless otherwise indicated, a heterocycloalkyl group has 2 to 10 carbon atoms in the ring. It should be understood that when referring to the number of carbon atoms in a heterocycloalkyl group, the number of carbon atoms in the heterocycloalkyl group is different from the total number of atoms (including heteroatoms) that make up the heterocycloalkyl group (i.e., the backbone atoms of the heterocycloalkyl ring).

[0092] The term "halo" or "halogen" means fluoro, chloro, bromo or iodo.

[0093] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens. These halogens may be the same or different. Non-limiting examples of haloalkyl include -CH2Cl, -CF3, -CHF2, -CH2CF3, -CF2CF3, etc.

[0094] The terms "fluoroalkyl" and "fluoroalkoxy" include alkyl and alkoxy groups, respectively, substituted with one or more fluorine atoms. Non-limiting examples of fluoroalkyl groups include -CF3, -CHF2, -CH2F, -CH2CF3, -CF2CF3, -CF2CF2CF3, -CF(CH3)2, and the like. Non-limiting examples of fluoroalkoxy groups include -OCF3, -OCHF2, -OCH2F, -OCH2CF3, -OCF2CF3, -OCF2CF2CF3, -OCF(CH3)2, and the like.

[0095] The term "heteroalkyl" refers to an alkyl group in which one or more backbone chain atoms are selected from atoms other than carbon, for example, oxygen, nitrogen, sulfur, phosphorus, silicon, or a combination thereof. The heteroatom may be located at any interior position of the heteroalkyl group. Examples include, but are not limited to, -CH2-O-CH3, -CH2-CH2-O-CH3, -CH2-NH-CH3, -CH2-CH2-NH-CH3, -CH2-N(CH3)-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2, -S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH2-NH-OCH3, -CH2-O-Si(CH3)3, -CH2-CH=N-OCH3, and -CH=CH-N(CH3)-CH3. Additionally, up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. In addition to the number of heteroatoms, a "heteroalkyl" group may have 1 to 6 carbon atoms.

[0096] The term "bond" or "single bond" refers to a chemical bond between two atoms, or between two moieties when the atoms connected by the bond are considered part of a larger substructure.

[0097] The term "moiety" refers to a specific segment or functional group of a molecule. A chemical moiety is typically a recognized chemical entity embedded in or attached to a molecule.

[0098] As used herein, a substituent "R" appearing alone without a numerical designation refers to a substituent selected from the group consisting of alkyl, haloalkyl, heteroalkyl, alkenyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heterocycloalkyl.

[0099] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0100] The term "optionally substituted" or "substituted" means that the referenced group may be substituted with one or more additional groups individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, -OH, alkoxy, aryloxy, alkylthio, arylthio, alkyl sulfoxide, aryl sulfoxide, alkyl sulfone, aryl sulfone, -CN, alkyne, C1-C6 alkylalkyne, halo, acyl, acyloxy, -CO2H, -CO2-alkyl, nitro, haloalkyl, fluoroalkyl, and amino, including mono- and disubstituted amino (e.g., -NH2, -NHR, -N(R)2), and protected derivatives thereof. For example, an optional substituent may be L s R s , where each L s is independently selected from a bond, -O-, -C(=O)-, -S-, -S(=O)-, -S(=O)2-, -NH-, -NHC(O)-, -C(O)NH-, S(=O)2NH-, -NHS(=O)2, -OC(O)NH-, -NHC(O)O-, -(C1-C6 alkyl)-, or -(C2-C6 alkenyl)-; and each R s Independently selected from H, (C1-C6 alkyl), (C3-C8 cycloalkyl), aryl, heteroaryl, heterocycloalkyl and C1-C6 heteroalkyl. Protecting groups that can form protected derivatives of the above substituents can be found in sources such as Greene and Wuts above.

[0101] As used herein, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

[0102] As used herein, the term "therapeutically effective amount" refers to an amount of a compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic) or (Id) that is effective to at least partially treat a condition described herein when administered to a mammal in need thereof.

[0103] The term "modulate" includes a decrease or increase in activity depending on the target molecule.

[0104] The term "activator" is used in this specification to denote any molecular substance that causes activation of a given receptor, whether the substance itself binds to the receptor or a metabolite of the substance binds to the receptor when the substance is topically applied. Thus, the activator may be a ligand for the receptor, or it may be an activator that is metabolized to a ligand for the receptor, i.e., a metabolite that is formed in the tissue and is the actual ligand.

[0105] The term "patient" or "mammal" refers to a human, non-human primate, dog, cat, cow, sheep, pig, mouse or other veterinary or laboratory mammal. Those skilled in the art recognize that a therapy that reduces the severity of pathology in one mammalian species may be predictive of the effect of the therapy in another mammalian species.

[0106] "Pharmaceutically acceptable salts" include acid addition salts and base addition salts. Any pharmaceutically acceptable salt of a compound described herein is intended to include any and all pharmaceutically suitable salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0107] "Pharmaceutically acceptable acid addition salts" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Thus, exemplary salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, octanoate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, etc. Also contemplated are salts of amino acids such as arginate, gluconate, and galacturonate (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66: 1-19 (1997)). The acid addition salts of basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt.

[0108] "Pharmaceutically acceptable base addition salts" refer to those salts that retain the biological effectiveness and properties of the free acids and are not biologically or otherwise undesirable. These salts are prepared by adding inorganic or organic bases to the free acids. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines. Salts derived from organic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenediphenylamine, N-methylglucamine, glucamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. See Berge et al., supra.

[0109] As used herein, "treat," "treat," "treat," "alleviate," or "ameliorate" are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results, including but not limited to therapeutic benefit and / or prophylactic benefit. By "therapeutic benefit" is meant the elimination or amelioration of the underlying condition being treated. Additionally, therapeutic benefit can be achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying condition, such that improvement is observed in the patient, although the patient is still afflicted with the underlying condition. For prophylactic benefit, the composition is administered to a patient at risk for developing a particular disease, or to a patient reporting one or more physiological symptoms of a disease, even if a diagnosis of the disease has not yet been made.

[0110] As used herein, "medically refractory" or "refractory" means that standard treatments are unable to induce remission of the disease. In some embodiments, the disease includes an inflammatory disease disclosed herein. Non-limiting examples of refractory inflammatory diseases include refractory Crohn's disease and refractory ulcerative colitis (e.g., medically refractory UC, or mrUC). Non-limiting examples of standard treatments include glucocorticoids, anti-TNFα therapy, anti-a4-b7 therapy (vedolizumab), anti-IL12p40 therapy (ustekinumab), thalidomide, and cytotoxins.

[0111] G protein-coupled receptor 35 (GPR35)

[0112] G protein-coupled receptor 35 (GPR35) is a receptor for kynurenic acid, an intermediate in the tryptophan metabolic pathway. GPR35 mediates calcium mobilization and the production of phosphoinositides. GPR35 and the nucleic acid encoding GPR35 are characterized by NCBI Entrez gene ID 2859. Studies have shown that GPR35 is involved in the regulation of inflammation, either through the presence of receptors on the surface of immune-specific cells or through activation by agonists that cause altered immune responses. Therefore, it is hypothesized that GPR35 and nucleic acids encoding GPR35 play a role in the pathology of inflammatory diseases, making GPR35 an attractive therapeutic target for the treatment of inflammatory diseases or conditions.

[0113] The compounds of Formula (I), (I') or (I") described herein are GPR35 modulators. In some embodiments, the compounds of Formula (I), (I') or (I") described herein are GPR35 agonists. In some embodiments, the compounds of Formula (I), (I') or (I") described herein are GPR35 inverse agonists. In some embodiments, the compounds of Formula (I), (I') or (I") described herein are GPR35 antagonists. The compounds of Formula (I), (I') or (I") described herein and compositions comprising these compounds can be used for inflammatory bowel disease.

[0114] In some embodiments, provided herein are compounds of formula (I"), or pharmaceutically acceptable salts or solvates thereof:

[0115]

[0116] in:

[0117] R 1 -CH2R 4 、-CN、-B(OH)2、-N(R 10 )2、-NR 10 C(O)R 9 , -C(O)OH, -CH2C(O)OH, -C(O)N(R 10 )2、-C(O)NHS(O)2N(R 10 )2. -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl, or optionally one, two or three R 8 A 5- or 6-membered heteroaryl group substituted with a group;

[0118] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)N(R10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0119] Each R 3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-NO2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 Cycloalkyl;

[0120] R 4 for

[0121] Each R 5 Independently selected from halogen, -CN, -OH, -OR 9 、-SR9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-R 9 、-C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 2-6 Alkenyl, -C 2-6 Alkenyl-C(O)OR 10 、C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, -C(O)OR 10 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl and -C 1-6 Alkyl-C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, -C(O)OR 10 、C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0122] R 6 -C(O)OR 7 、-C(O)NHS(O)2N(R 10 )2.

[0123] R 7 Independently selected from H and C 1-6 alkyl;

[0124] Each R 8 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0125] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR 11 、-N(R 11 )2、C 1-6 Alkyl, C 3-8 Cycloalkyl, -N(R 11 )C(O)R 12 、-C(O)R 12 and -C(O)OR 12 substituted by a group;

[0126] Each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0127] Each R 11 Independently selected from H and C 1-6 alkyl;

[0128] Each R 12 Independently selected from H and C 1-6 alkyl;

[0129] Each R 13 Independently selected from C 1-6 alkyl;

[0130] m is 1, 2, 3 or 4;

[0131] n is 0, 1, 2, or 3;

[0132] p is 0, 1, 2, 3, 4 or 5; and

[0133] q is 0, 1, 2, 3, or 4;

[0134] or a pharmaceutically acceptable salt or solvate thereof.

[0135] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 0, 1 or 2. In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 0. In some embodiments is a compound of Formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 1. In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 2. In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 1 or 2. In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl and C 1-9 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl and C 1-9 heteroaryl, and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and C 1-9 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-C(O)NHS(O)2N(R10 )2、-C(O)OR 10 、-C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and C 1-9 heteroaryl, and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OR 9 、-C(O)OR 10 、-C(O)N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from -OR 9 、-C(O)OR 10 、-C(O)N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -C(O)OR 10 In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from -C(O)OR 10 , and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OH, -OR 9 and -C 1-6 Alkyl-C(O)OR 10 In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OH, -OR 9 and -C 1-6 Alkyl-C(O)OR 10 , and R 9 is optionally -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1, and R 5 Independently selected from -C(O)OH.

[0136] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 substituted 5-membered heteroaryl, wherein the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl and thiadiazolyl. In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8 independently selected from halogen, -C(O)OR 10 、C 1-6 Alkyl and -C 1-6 Alkyl-C(O)OR 10 In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8 Independently selected from -C(O)OR 10 In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl and isoxazolyl. In some embodiments, it is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl group selected from pyridyl and pyrimidinyl.

[0137] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2. In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2- 9 heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1-C(O)N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 independently selected from H and optionally substituted by -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 independently selected from H and C optionally substituted with -C(O)OH 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 Together with the nitrogen atom to which they are attached, they form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0138] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1-N(R 10 )2. In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 independently selected from H and optionally substituted by -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 independently selected from H and C optionally substituted with -C(O)OH 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 Together with the nitrogen atom to which they are attached, they form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0139] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is -C(O)OH.

[0140] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is -CH2C(O)OH.

[0141] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)NHS(O)2N(R 10 )2.

[0142] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for

[0143] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and m is 2. In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for And m is 1.

[0144] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R1 -CH2R 4 And R 4 for In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for and q is 0. In some embodiments is a compound of Formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 -C(O)OR 7 In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 -C(O)NHS(O)2N(R 10 )2. In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 for In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 for

[0145] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 H, -OH, -N(R 10 )2 or -OC 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 For-OC 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Is H. In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 )2.

[0146] In some embodiments is a compound of Formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0147] In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3. In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 Independently selected from halogen, -CN, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen, -OR9 、-N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2 and C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen and C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OH, -OR 9 、-N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 and C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 For-OR 9 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 C 3-8 In some embodiments, the compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 It is cyclopentyl.

[0148] In some embodiments, provided herein is a compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof:

[0149]

[0150] in:

[0151] R 1 -CH2R 4 、-CN、-B(OH)2、-N(R 10 )2、-NR 10 C(O)R 9 , -C(O)OH, -CH2C(O)OH, -C(O)N(R 10 )2、-C(O)NHS(O)2N(R 10 )2. -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl, or optionally one, two or three R 8 A 5- or 6-membered heteroaryl group substituted with a group;

[0152] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)N(R 10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0153] Each R 3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 Cycloalkyl;

[0154] R 4 for

[0155] Each R 5 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-R 9 、-C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 2-6 Alkenyl, -C 2-6Alkenyl-C(O)OR 10 、C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0156] R 6 -C(O)OR 7 、-C(O)NHS(O)2N(R 10 )2.

[0157] Each R 7 Independently selected from H and C 1-6 alkyl;

[0158] Each R 8 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0159] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR11 、-N(R 11 )2、C 1-6 Alkyl, C 3-8 Cycloalkyl, -N(R 11 )C(O)R 12 、-C(O)R 12 and -C(O)OR 12 substituted by a group;

[0160] Each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0161] Each R 11 Independently selected from H and C 1-6 alkyl;

[0162] R 12 Independently selected from H and C 1-6 alkyl;

[0163] n is 0, 1, 2, or 3;

[0164] p is 0, 1, 2, 3, 4 or 5; and

[0165] q is 0, 1, 2, 3 or 4.

[0166] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 0, 1 or 2. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 0. In some embodiments is a compound of Formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 1. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 2. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 1 or 2. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl and C 1-9 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1for p is 1 or 2, each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl and C 1-9 heteroaryl, and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and C 1-9In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and C 1-9 heteroaryl, and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OR 9 、-C(O)OR 10 、-C(O)N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from -OR 9 、-C(O)OR 10 、-C(O)N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -C(O)OR 10 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from -C(O)OR 10 , and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OH, -OR 9 and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OH, -OR 9 and -C 1-6 Alkyl-C(O)OR 10 , and R 9 is optionally -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1, and R 5 Independently selected from -C(O)OH.

[0167] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 substituted 5-membered heteroaryl, wherein the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl and thiadiazolyl. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8 independently selected from halogen, -C(O)OR 10 、C 1-6 Alkyl and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8 Independently selected from -C(O)OR 10 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl and isoxazolyl. In some embodiments, it is a compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl group selected from pyridyl and pyrimidinyl.

[0168] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2- 9 heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound is of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound is of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 independently selected from H and optionally substituted by -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 independently selected from H and C optionally substituted with -C(O)OH 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10Together with the nitrogen atom to which they are attached, they form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0169] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound is of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound is of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 independently selected from H and optionally substituted by -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10independently selected from H and C optionally substituted with -C(O)OH 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 Together with the nitrogen atom to which they are attached, they form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0170] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is -C(O)OH.

[0171] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is -CH2C(O)OH.

[0172] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)NHS(O)2N(R 10 )2.

[0173] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for

[0174] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 And R 4 for In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1-CH2R 4 , R 4 for and q is 0. In some embodiments is a compound of Formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 -C(O)OR 7 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 -C(O)NHS(O)2N(R 10 )2. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 for In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 for

[0175] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 H, -OH, -N(R 10 )2 or -OC 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For-OC 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 )2.

[0176] In some embodiments is a compound of Formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0177] In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 Independently selected from halogen, -CN, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen, -OR 9 、-N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2 and C1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen and C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OH, -OR 9 、-N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 and C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 For-OR 9 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 C 3-8 In some embodiments, the compound of formula (I'), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 It is cyclopentyl.

[0178] In some embodiments, provided herein are compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof:

[0179]

[0180] in:

[0181] R 1 -CH2R 4 、-CN、-B(OH)2、-N(R10 )2、-NR 10 C(O)R 9 , -C(O)OH, -CH2C(O)OH, -C(O)N(R 10 )2、-C(O)NHS(O)2N(R 10 )2. -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl, or optionally one, two or three R 8 A 5- or 6-membered heteroaryl group substituted with a group;

[0182] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)N(R 10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0183] Each R 3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 Cycloalkyl;

[0184] R 4 for

[0185] Each R 5 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0186] R 6 -C(O)OR 7 、-C(O)NHS(O)2N(R 10 )2.

[0187] Each R 7 Independently selected from H and C 1-6 alkyl;

[0188] Each R 8 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0189] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR 11 、-N(R 11 )2、C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 and -C(O)OR 12 substituted by a group;

[0190] Each R10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0191] Each R 11 Independently selected from H and C 1-6 alkyl;

[0192] R 12 Independently selected from H and C 1-6 alkyl;

[0193] n is 0, 1, 2, or 3;

[0194] p is 0, 1, 2, 3, 4 or 5; and

[0195] q is 0, 1, 2, 3 or 4.

[0196] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 0, 1 or 2. In some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 0. In some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 1. In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 2. In some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for and p is 1 or 2. In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl and C 1-9 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl and C 1-9 heteroaryl, and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and C 1-9 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2、-NR 10 C(O)R9 、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and C 1-9 heteroaryl, and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OR 9 、-C(O)OR 10 、-C(O)N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 In some embodiments is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from -OR 9 、-C(O)OR 10 、-C(O)N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -C(O)OR 10 In some embodiments is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, each R 5 Independently selected from -C(O)OR 10 , and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OH, -OR 9 and -C 1-6 Alkyl-C(O)OR 10In some embodiments is a compound of formula (I"), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OH, -OR 9 and -C 1-6 Alkyl-C(O)OR 10 , and R 9 is optionally -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1, and R 5 Independently selected from -C(O)OH.

[0197] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 substituted 5-membered heteroaryl, wherein the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl and thiadiazolyl. In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8independently selected from halogen, -C(O)OR 10 、C 1-6 Alkyl and -C 1-6 Alkyl-C(O)OR 10 In some embodiments is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8 Independently selected from -C(O)OR 10 In some embodiments is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl and isoxazolyl. In some embodiments, it is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl group selected from pyridyl and pyrimidinyl.

[0198] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2. In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2- 9 heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl and C 2-9Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 independently selected from H and optionally substituted by -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and each R 10 independently selected from H and C optionally substituted with -C(O)OH 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 Together with the nitrogen atom to which they are attached, they form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0199] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2. In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 Independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 independently selected from H and optionally substituted by -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and each R 10 independently selected from H and C optionally substituted with -C(O)OH 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R10 )2 and the two R 10 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 Together with the nitrogen atom to which they are attached, they form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0200] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is -C(O)OH.

[0201] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is -CH2C(O)OH.

[0202] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)NHS(O)2N(R 10 )2.

[0203] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for

[0204] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 And R 4 for In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for and q is 0. In some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 -C(O)OR 7 In some embodiments is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4for q is 0, and R 6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 -C(O)NHS(O)2N(R 10 )2. In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 for In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -CH2R 4 , R 4 for q is 0, and R 6 for

[0205] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 H, -OH, -N(R 10 )2 or -OC 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For-OC 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 )2.

[0206] In some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0207] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3. In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 Independently selected from halogen, -CN, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen, -OR 9 、-N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2 and C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen and C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OH, -OR 9 、-N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6Alkyl-OR 9 and C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 For-OR 9 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 C 3-8 In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 It is cyclopentyl.

[0208] In some embodiments, provided herein is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof:

[0209]

[0210] in:

[0211] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)N(R 10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0212] Each R3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 Cycloalkyl;

[0213] Each R 5 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0214] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR 11 、-N(R 11 )2、C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 and -C(O)OR 12 substituted by a group;

[0215] Each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0216] Each R 11 Independently selected from H and C 1-6 alkyl;

[0217] R 12 Independently selected from H and C 1-6 alkyl;

[0218] n is 0, 1, 2 or 3; and

[0219] p is 0, 1, 2, 3, 4 or 5.

[0220] In some embodiments, it is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0, 1 or 2. In some embodiments, it is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0. In some embodiments, it is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1. In some embodiments, it is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 2. In some embodiments, it is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2. In some embodiments, it is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2, and each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl and C 1-9 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2, each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl and C 1-9 heteroaryl, and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2, and each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and C 1-9 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2, each R 5 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10)2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 and C 1-9 heteroaryl, and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2, and each R 5 Independently selected from -OR 9 、-C(O)OR 10 、-C(O)N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2, each R 5 Independently selected from -OR 9 、-C(O)OR 10 、-C(O)N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2, and each R 5 Independently selected from -C(O)OR 10 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1 or 2, each R 5 Independently selected from -C(O)OR 10 , and each R 10 Independently selected from H and C 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R 5 Independently selected from -OH, -OR 9 and -C 1-6 Alkyl-C(O)OR 10 In some embodiments is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 for p is 1 or 2, and each R5 Independently selected from -OH, -OR 9 and -C 1-6 Alkyl-C(O)OR 10 , and R 9 is optionally -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1, and R 5 Independently selected from -C(O)OH.

[0221] In some embodiments, the compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 H, -OH, -N(R 10 )2 or -OC 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For-OC 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 )2.

[0222] In some embodiments is a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0223] In some embodiments, the compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3. In some embodiments, the compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3 and each R 3 Independently selected from halogen, -CN, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R9 、-C(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen, -OR 9 、-N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2 and C 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen and C 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OH, -OR 9 、-N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 and C 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 For-OR 9 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 C 3-8 In some embodiments, the compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 It is cyclopentyl.

[0224] In some embodiments, provided herein is a compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof:

[0225]

[0226] in:

[0227] R 1 is optionally replaced by one, two or three R 8 A 5- or 6-membered heteroaryl group substituted with a group;

[0228] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)N(R 10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0229] Each R 3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 Cycloalkyl;

[0230] Each R 8 Independently selected from halogen, -OH, -OR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)NHS(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R10 )2. -C 1-6 Alkyl-C(O)OR 10 、C 1-6 Halogenated alkyl, C 1-6 Halogenated alkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl and C 1-9 Heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl and C 1-9 Heteroaryl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and C 2-9 is substituted with a heterocycloalkyl group; and wherein C 2-9 Heterocycloalkyl is optionally substituted by one, two or three independently selected from halogen, C 1-6 Alkyl, C 1-6 substituted with haloalkyl and oxo groups;

[0231] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR 11 、-N(R 11 )2、C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 and -C(O)OR 12 substituted by a group;

[0232] Each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0233] Each R 11 Independently selected from H and C 1-6 alkyl;

[0234] R 12 Independently selected from H and C 1-6 alkyl; and

[0235] n is 0, 1, 2 or 3.

[0236] In some embodiments, the compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, is selected from the group consisting of oxazolyl, thiazolyl, pyrazolyl, furyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl and thiadiazolyl. 1 is optionally replaced by one or two R 8In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, is a 5-membered heteroaryl group substituted by a 5-membered heteroaryl group, wherein the 5-membered heteroaryl group is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl and isoxazolyl. 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one, two or three R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally replaced by one or two R 8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8 independently selected from halogen, -C(O)OR 10 、C 1-6 Alkyl and -C 1-6 Alkyl-C(O)OR 10 In some embodiments is a compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 8 Independently selected from -C(O)OR 10 In some embodiments is a compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl and isoxazolyl. In some embodiments, it is a compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl group selected from pyridyl and pyrimidinyl.

[0237] In some embodiments, the compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 H, -OH, -N(R 10 )2 or -OC 1-6 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For-OC 1-6 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments is a compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2-N(R 10 )2.

[0238] In some embodiments is a compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0239] In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3. In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3 and each R 3 Independently selected from halogen, -CN, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen, -OR 9 、-N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2 and C 1-6 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen and C 1-6In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OH, -OR 9 、-N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 and C 1-6 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 For-OR 9 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 C 3-8 In some embodiments, the compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 It is cyclopentyl.

[0240] In some embodiments, provided herein is a compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof:

[0241]

[0242] in:

[0243] R 1 -C(O)N(R 10 )2;

[0244] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10)2、-C(O)N(R 10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0245] Each R 3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 Cycloalkyl;

[0246] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR 11 、-N(R 11 )2、C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 and -C(O)OR 12 substituted by a group;

[0247] Each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0248] Each R 11 Independently selected from H and C 1-6 alkyl;

[0249] R 12 Independently selected from H and C 1-6 alkyl; and

[0250] n is 0, 1, 2 or 3.

[0251] In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 Independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 independently selected from H and optionally substituted by -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 independently selected from H and C optionally substituted with -C(O)OH 1-6 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 )2 and the two R 10 Together with the nitrogen atom to which they are attached, they form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0252] In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 H, -OH, -N(R 10 )2 or -OC 1-6 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For-OC 1-6 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments is a compound of Formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 )2.

[0253] In some embodiments is a compound of Formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0254] In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3. In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3 and each R 3 Independently selected from halogen, -CN, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen, -OR 9 、-N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2 and C 1-6 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen and C 1-6 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OH, -OR 9 、-N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 and C 1-6 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 For-OR 9 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 C 3-8 In some embodiments, the compound of formula (Ic), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 It is cyclopentyl.

[0255] In some embodiments, provided herein is a compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof:

[0256]

[0257] in:

[0258] R 1 -N(R 10 )2;

[0259] R 2 H, -OH, -N(R 10 )2, -NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)N(R 10 )2、-OC(O)N(R 10 )2. -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl;

[0260] Each R 3 Independently selected from halogen, -CN, -OH, -OR 9 、-SR 9 、-N(R 10 )2、-S(O)R 9 、-S(O)2R9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-OC(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、-NR 10 C(O)OR 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8 Cycloalkyl;

[0261] Each R 9 Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl and -C 1-6 Alkyl-C 2-9 Heteroaryl is optionally substituted by one or more independently selected from C 1-6 Alkyl, -OR 11 、-N(R 11 )2、C 1-6 Alkyl, C 3-8Cycloalkyl, -C(O)R 12 and -C(O)OR 12 substituted by a group;

[0262] Each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 or two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 a 5- or 6-membered heterocycloalkyl ring substituted with alkyl, oxo, and -C(O)OH groups;

[0263] Each R 11 Independently selected from H and C 1-6 alkyl;

[0264] R 12 Independently selected from H and C 1-6 alkyl; and

[0265] n is 0, 1, 2 or 3.

[0266] In some embodiments is a compound of Formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 Independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl and C 2-9 Heteroaryl, wherein C 1-6 Alkyl, phenyl and C 2-9 Heteroaryl is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, -N(R 11 )2 and -C(O)OR 12 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 independently selected from H and optionally substituted by -C(O)OR 12 Replaced by C 1-6 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 10 independently selected from H and C optionally substituted with -C(O)OH 1-6 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from C 1-6 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 )2 and the two R 10 Together with the nitrogen atom to which they are attached, they form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0267] In some embodiments is a compound of Formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 H, -OH, -N(R 10 )2 or -OC 1-6In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For-OC 1-6 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments is a compound of Formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 )2.

[0268] In some embodiments is a compound of Formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

[0269] In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3. In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3 and each R 3 Independently selected from halogen, -CN, -OR 9 、-N(R 10 )2、-S(O)2R 9 、-NHS(O)2R 9 、-S(O)2N(R 10 )2、-C(O)R 9 、-C(O)OR 10 、-OC(O)R 9 、-C(O)N(R 10 )2、-NR 10 C(O)N(R 10 )2、-NR 10 C(O)R 9 、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 、-C 1-6 Alkyl-N(R 10 )2、C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl and -C 1-6 Alkyl-C 3-8In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen, -OR 9 、-N(R 10 )2、-C(O)OR 10 、-C(O)N(R 10 )2 and C 1-6 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, 2 or 3 and each R 3 independently selected from halogen and C 1-6 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OH, -OR 9 、-N(R 10 )2、C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 and C 1-6 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 Selected from halogen, -OR 9 and C 1-6 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 For-OR 9 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 C 3-8 In some embodiments, the compound of formula (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1, R 3 For-OR 9 , and R 9 It is cyclopentyl.

[0270] In some embodiments, provided herein is a compound selected from the group consisting of:

[0271]

[0272]

[0273]

[0274] or a pharmaceutically acceptable salt or solvate thereof.

[0275] In some embodiments, provided herein is a compound selected from the group consisting of:

[0276]

[0277] or a pharmaceutically acceptable salt or solvate thereof.

[0278] In some embodiments, provided herein is a compound selected from the group consisting of:

[0279]

[0280]

[0281]

[0282] or a pharmaceutically acceptable salt or solvate thereof.

[0283] In some embodiments, provided herein is a compound selected from the group consisting of:

[0284] or a pharmaceutically acceptable salt or solvate thereof.

[0285] In some embodiments, provided herein is a compound selected from the group consisting of:

[0286] or a pharmaceutically acceptable salt or solvate thereof.

[0287] In some embodiments, provided herein is a compound selected from the group consisting of:

[0288]

[0289] or a pharmaceutically acceptable salt or solvate thereof.

[0290] Any combination of the groups described above for each variable is contemplated herein. Throughout the specification, groups and substituents thereof may be chosen by one skilled in the art to provide stable moieties and compounds.

[0291] In some embodiments, the therapeutic agent (e.g., a compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic), or (Id)) is present in the pharmaceutical composition as a pharmaceutically acceptable salt. In some embodiments, any of the compounds described above are suitable for any of the methods or compositions described herein.

[0292] Other forms of the compounds disclosed herein

[0293] Isomers

[0294] In addition, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds proposed herein include all cis, trans, cis, trans, entgegen (E) and zusammen (Z) isomers and their corresponding mixtures. In some cases, the compounds exist as tautomers. The compounds described herein include all possible tautomers within the general formula described herein. In some cases, the compounds described herein have one or more chiral centers, and each center exists in the R configuration or the S configuration. The compounds described herein include all diastereoisomers, enantiomers and epimeric forms, and their corresponding mixtures. In other embodiments of the compounds and methods provided herein, the enantiomers and / or mixtures of diastereoisomers produced by a single preparation step, combination or mutual conversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as optically pure enantiomers by chiral chromatographic separation of the racemic mixture. In some embodiments, by making the racemic mixture of compound react with optically active resolving agent to form a pair of diastereomeric compounds, separate diastereomers and reclaim optically pure enantiomers, so that compound as described herein is prepared into its independent stereoisomer. In some embodiments, separable complex is preferred (for example, crystalline diastereomeric salt). In some embodiments, diastereomers have different physical properties (for example, melting point, boiling point, solubility, reactivity, etc.) and are separated by utilizing these dissimilarity. In some embodiments, diastereomers are separated by chiral chromatography, or preferably by separation / splitting technology based on solubility difference. In some embodiments, subsequently by not causing any practical means of racemization, optically pure enantiomers are reclaimed together with resolving agent.

[0295] Labeled compounds

[0296] In some embodiments, the compounds described herein exist in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds in the form of pharmaceutical compositions. Therefore, in some embodiments, the compounds disclosed herein include isotopically labeled compounds that are identical to those listed herein except that one or more atoms are replaced by atoms having an atomic mass or mass number that is different from the atomic mass or mass number typically found in nature. Examples of isotopes incorporated into the compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as, respectively. 2 H. 3 H. 13 C. 14 C. l5 N. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds described herein containing the above-mentioned isotopes and / or other isotopes of other atoms and pharmaceutically acceptable salts, esters, solvates, hydrates or derivatives thereof are within the scope of the present invention. Certain isotopically labeled compounds, for example, compounds into which radioactive isotopes such as 3 H and 14 C are useful in drug and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. In addition, the use of heavy isotopes (such as deuterium, i.e. 2 H) substitutions confer certain therapeutic advantages. In some embodiments, isotopically labeled compounds, or pharmaceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof, are prepared by any suitable method.

[0297] In some embodiments, the compounds described herein are labeled by other means including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0298] Pharmaceutically acceptable salts

[0299] In some embodiments, the compounds described herein exist as pharmaceutically acceptable salts thereof. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts in the form of pharmaceutical compositions.

[0300] In some embodiments, the compounds described herein have acidic or basic groups and therefore react with some inorganic or organic bases, and any base or acid among inorganic and organic acids, to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds described herein, or by reacting the purified compound in free form with a suitable acid or base, respectively, and isolating the salt thus formed.

[0301] Solvates

[0302] In some embodiments, the compounds described herein exist as solvates. In some embodiments, methods of treating a disease are performed by administering such solvates. Further described herein are methods of treating a disease by administering such solvates in the form of pharmaceutical compositions.

[0303] Solvates contain stoichiometric or non-stoichiometric amounts of solvent, and in some embodiments, solvates are formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed in the processes described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from an aqueous / organic solvent mixture using organic solvents including, but not limited to, dioxane, tetrahydrofuran, or MeOH. In addition, the compounds provided herein exist in unsolvated and solvated forms. Generally, for the compounds and methods provided herein, the solvated forms are considered equivalent to the unsolvated forms.

[0304] Synthesis of compounds

[0305] In some embodiments, the synthesis of the compounds described herein is achieved using means described in the chemical literature, using methods described herein, or by a combination thereof. Additionally, solvents, temperatures, and other reaction conditions set forth herein may be varied.

[0306] In other embodiments, starting materials and reagents used to synthesize compounds described herein are synthesized or obtained from commercial sources such as, but not limited to, Sigma-Aldrich, Fischer Scientific (Fischer Chemicals), and Acros Organics.

[0307] In further embodiments, the compounds described herein and other related compounds having various substituents are synthesized using the techniques and materials described herein, as well as those recognized in the art, such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplements (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Edition, (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4th Edition, Volumes A and B (Plenum 2000, 2001), and Green and Wuts, Protective Groups in Organic Synthesis 3rd Edition (Wiley 1999) (all of which are incorporated by reference for such disclosure). General methods for preparing the compounds disclosed herein can be derived from reactions, and these reactions can be modified using appropriate reagents and conditions to introduce the various moieties found in the general formulas provided herein. As a guide, the following synthetic methods can be used.

[0308] Use of protecting groups

[0309] In the reactions described, when reactive functional groups are desired in the final product, it may be necessary to protect the reactive functional groups, e.g., hydroxyl, amino, imino, sulfhydryl, or carboxyl groups, to prevent them from participating unnecessarily in the reaction. Protecting groups are used to block some or all of the reactive moieties and prevent these groups from participating in the chemical reaction until the protecting groups are removed. Preferably, each protecting group can be removed by a different means. Protecting groups that are removed under completely different reaction conditions satisfy the need for differentiated removal.

[0310] Protecting groups can be removed by acid, base, reducing conditions (e.g., hydrogenolysis), and / or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal, and tert-butyldimethylsilyl are acid labile and can be used to protect carboxyl and hydroxyl reactive moieties in the presence of amino groups protected with Cbz groups (which can be removed by hydrogenolysis) and Fmoc groups (which are base labile). Carboxylic acid and hydroxyl reactive moieties can be blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl in the presence of amines blocked with acid labile groups such as tert-butyl carbamate, or with carbamates that are stable in both acid and base but can be removed by hydrolysis.

[0311] Carboxylic acid and hydroxyl reactive moieties can be blocked with hydrolytically removable protecting groups such as benzyl, while amine groups capable of hydrogen bonding with acids can be blocked with base-labile groups such as Fmoc. Carboxylic acid reactive moieties can be protected by conversion to monoester compounds as exemplified herein, including conversion to alkyl esters, or can be blocked with oxidatively removable protecting groups such as 2,4-dimethoxybenzyl, while co-existing amino groups can be blocked with fluoride-labile silylcarbamates.

[0312] In the presence of acid and base protecting groups, the allyl blocking group is useful because it is stable and can be subsequently removed by metal or pi-acid catalysts. For example, in the presence of acid-labile tert-butyl carbamate or base-labile acetamide protecting groups, Pd 0 The catalyzed reaction deprotects the allyl-blocked carboxylic acid. Another form of protecting group is a resin to which a compound or intermediate can be attached. As long as the residue is attached to the resin, the functional group is blocked and thus cannot react. Once released from the resin, the functional group is available for reaction.

[0313] In general, blocking / protecting groups may be selected from:

[0314]

[0315] Other protecting groups, and detailed descriptions of suitable techniques for their creation and removal, are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated by reference for such disclosure.

[0316] Treatment and prevention methods

[0317] In some embodiments, a method of treating an inflammatory bowel disease in a patient in need thereof comprises administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic), or (Id), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating an inflammatory bowel disease in a patient in need thereof comprises administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic), or (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein the inflammatory bowel disease is selected from Crohn's disease, ulcerative colitis, and perianal Crohn's disease. In some embodiments is a method of treating an inflammatory bowel disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic), or (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein the inflammatory bowel disease is Crohn's disease. In some embodiments is a method of treating an inflammatory bowel disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic), or (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein the inflammatory bowel disease is ulcerative colitis. In some instances, the ulcerative colitis is a severe form of ulcerative colitis. In some instances, the severe form of ulcerative colitis is medically refractory ulcerative colitis. In some embodiments is a method of treating an inflammatory bowel disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic), or (Id), or a pharmaceutically acceptable salt or solvate thereof, wherein the inflammatory bowel disease is perianal Crohn's disease.

[0318] Pharmaceutical compositions and methods of administration

[0319] In certain embodiments, the compounds described herein are administered as pure chemicals. In other embodiments, the compounds described herein are combined with a pharmaceutically suitable or acceptable carrier (also herein a pharmaceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier) selected based on the selected route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21st ed. Mack Pub. Co., Easton, PA (2005)).

[0320] Thus, provided herein is a pharmaceutical composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers. A carrier (or excipient) is acceptable or suitable if it is compatible with the other ingredients of the composition and is not harmful to the recipient (i.e., subject) of the composition.

[0321] In some embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of Formula (I'), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of Formula (I"), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of Formula (Ic), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (Id) or a pharmaceutically acceptable salt or solvate thereof.

[0322] Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt thereof. In some embodiments, a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I'), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I"), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ib), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition is provided, which consists essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ic), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a pharmaceutical composition is provided, which consists essentially of a pharmaceutically acceptable carrier and a compound of Formula (Id), or a pharmaceutically acceptable salt or solvate thereof.

[0323] In certain embodiments, the compounds described herein are substantially pure in that they contain less than about 5%, or less than about 1%, or less than about 0.1% of other small organic molecules, such as, for example, contaminating intermediates or by-products produced in one or more steps of the synthetic methods.

[0324] These formulations include those suitable for oral, topical, buccal, parenteral (eg, subcutaneous, intramuscular, intradermal, or intravenous) or aerosol administration.

[0325] Exemplary pharmaceutical compositions are used in the form of pharmaceutical preparations, such as solid, semisolid, or liquid forms, comprising one or more disclosed compounds as active ingredients in admixture with organic or inorganic carriers or excipients suitable for external, enteral, or parenteral application. In some embodiments, the active ingredients are compounded with, for example, generally nontoxic, pharmaceutically acceptable carriers for tablets, pills, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for application. The pharmaceutical compositions contain an amount of the active compound of interest sufficient to produce the desired effect on the disease process or condition.

[0326] In some embodiments, to prepare solid compositions such as tablets, the main active ingredient is mixed with a pharmaceutical carrier (e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gum) and other pharmaceutical diluents (e.g., water) to form a solid preformulation composition comprising a uniform mixture of the disclosed compound or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as uniform, it is meant that the active ingredient is evenly dispersed throughout the composition so that the composition can be easily subdivided into equivalent unit dosage forms, such as tablets, pills, and capsules.

[0327] In solid dosage forms for oral administration (capsules, tablets, pills, lozenges, powders, granules, etc.), the compositions of the present invention are mixed with one or more pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate and / or any of the following: (1) fillers or extenders such as starch, cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sucrose, glucose, mannitol and / or silicic acid; (2) binders such as carboxymethylcellulose, hydroxypropyl methylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or gum arabic; (3) moisturizers.

[0014] Examples of the present invention include, but are not limited to, glycerol; (4) disintegrants such as crospovidone, cross-linked sodium carboxymethyl cellulose, sodium starch glycolate, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) dissolution retardants such as paraffin; (6) absorption accelerators such as quaternary ammonium compounds; (7) wetting agents such as sodium docusate, cetyl alcohol, and glyceryl monostearate; (8) absorbents such as kaolin and bentonite; (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets, and pills, in some embodiments, the composition includes a buffering agent. In some embodiments, similar types of solid compositions are also employed as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.

[0328] In some embodiments, tablets are made by optionally compressing or molding with one or more auxiliary ingredients. In some embodiments, compressed tablets are prepared using a binder (e.g., gelatin or hydroxypropyl methylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), a surfactant, or a dispersant. In some embodiments, molded tablets are prepared by molding a mixture of the present composition moistened with an inert liquid diluent in a suitable machine. In some embodiments, tablets and other solid dosage forms, such as lozenges, capsules, pills, and granules, are scored or prepared with coatings and shells, such as enteric coatings and other coatings.

[0329] Pharmaceutical compositions suitable for parenteral administration comprise the compositions of the present invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions or sterile powders to be reconstituted into sterile injectable solutions or dispersions immediately before use, which in some embodiments contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.

[0330] Examples of suitable aqueous and non-aqueous carriers for use in pharmaceutical compositions include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate and cyclodextrins. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by maintaining the desired particle size in the case of dispersions, and by the use of surfactants.

[0331] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, as well as powders. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the composition of the present invention, in some embodiments, the liquid dosage form further contains an inert diluent, for example, water or other solvents, solubilizers, and emulsifiers, such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (particularly cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofuranol, polyethylene glycol, fatty acid esters of sorbitan, cyclodextrins, and mixtures thereof.

[0332] In some embodiments, suspensions contain, in addition to the compositions of the present invention, suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0333] In some embodiments, powders and sprays contain, in addition to the compositions of the present invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures of these substances. In some embodiments, sprays additionally contain conventional propellants such as chlorofluorocarbons and volatile unsubstituted hydrocarbons such as butane and propane.

[0334] Alternatively, the compositions and compounds disclosed herein are administered by aerosol. This is achieved by preparing aqueous aerosols, liposome preparations, or solid particles containing the compound. In some embodiments, non-aqueous (e.g., fluorocarbon propellants) suspensions are used. In some embodiments, sonic nebulizers are used because they minimize the exposure of the medicament to shear forces (which cause degradation of the compound contained in the compositions of the present invention). Typically, aqueous aerosols are prepared by formulating an aqueous solution or suspension of the compositions of the present invention with a conventional pharmaceutically acceptable carrier and stabilizer. Carriers and stabilizers vary with the requirements of the specific target composition, but typically include nonionic surfactants (Tween, Pluronics, or polyethylene glycol), non-toxic proteins such as serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars, or sugar alcohols. Aerosols are typically prepared from isotonic solutions.

[0335] In some embodiments, compositions and compounds as herein described are applied to a subject in a biocompatible form suitable for topical administration.Topical administration can be presented in the form of an aerosol, a semisolid pharmaceutical composition, a powder or a solution. So-called term "semisolid composition" refers to an ointment, a cream, a salve, a jelly or other pharmaceutical compositions with a consistency that is substantially similar and suitable for application to the skin. Examples of semisolid compositions are provided in Chapter 17 of The Theory and Practice of Industrial Pharmacy by Lachman, Lieberman and Kanig, published by Lea and Febiger (1970), and Remington's Pharmaceutical Sciences, published by Mack Publishing Company, the 15th edition (1975).

[0336] Skin patches are another method for transdermal delivery of therapeutic or pharmaceutical compositions described herein. Patches can provide absorption enhancers, such as DMSO, to increase the absorption of the compound. Patches can include those that control the rate at which the drug is delivered to the skin.

[0337] Ointment, paste, emulsifiable paste and gel can also contain excipient, as starch, tragacanth, cellulose derivative, polyethylene glycol, polysiloxane, bentonite, silicic acid and talcum, or its mixture.Powder and spray can also contain excipient, as lactose, talcum, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or the mixture of these materials.Can be used for the preparation of any known means of aerosol medicine by conventional nanocrystalline antimicrobial metal solution is converted into aerosol or spray.Usually, such method comprises that usually use inert carrier gas that the container of solution is pressurized or pressurization means is provided, and pressurized gas is passed through aperture.Spray can contain conventional propellant in addition, as chlorofluorocarbon and volatile unsubstituted hydrocarbon, as butane and propane.

[0338] The dosage of the composition comprising at least one compound described herein varies depending on the condition of the patient (eg, human), ie, the stage of the disease, general health, age, and other factors.

[0339] Pharmaceutical composition is used in a manner suitable for the disease to be treated (or prevented). Appropriate dosage and suitable administration duration and frequency will depend on factors such as the patient's condition, the type and severity of the patient's disease, the specific form of active ingredient and the method of administration. Usually, suitable dosage and treatment regimen provide compositions in an amount that is enough to provide treatment and / or prevention benefit (for example, improved clinical outcome, such as more frequent complete or partial relief, or longer disease-free and / or overall survival period, or the alleviating of symptom severity). Usually experimental models and / or clinical trials are used to determine optimal dose. In some embodiments, optimal dose depends on the patient's body mass, body weight or blood volume.

[0340] Oral dosages generally range from about 1.0 mg to about 1000 mg, one to four or more times a day.

[0341] Repeated dosages may be administered depending on the pharmacokinetic parameters of the dosage formulation and the route of administration utilized.

[0342] It is particularly advantageous to formulate the compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrete units suited as uniform dosages for the mammalian subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit form is dictated by and directly dependent on (a) the unique properties of the compound of Formula (I), (I'), (I"), (Ia), (Ib), (Ic) or (Id) and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such active compounds for treating individual susceptibility. One of ordinary skill in the art can readily calculate specific dosages, for example, based on the patient's approximate weight or body surface area or the volume of body space to be occupied. The dosage will also be calculated based on the particular route of administration chosen. The exact dosage will be determined in conjunction with standard dose-response studies. It will be understood that the actual amount of the composition administered will be determined by the practitioner in accordance with the relevant circumstances, including the condition or conditions to be treated, the choice of composition to be administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the route of administration chosen.

[0343] Toxicity and therapeutic efficacy of compounds of Formula (I), (I'), (I"), (Ia), (Ib), (Ic), or (Id) can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD 50 (the dose that is lethal to 50% of the population) and ED 50 The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as LD 50 / ED 50 ratio.

[0344] Example

[0345] The following examples are offered for illustrative purposes and are not intended to limit the scope of the claims presented herein.

[0346] As used above, throughout the specification of the present invention, unless otherwise indicated, the following abbreviations shall be understood to have the following meanings:

[0347] ACN or MeCN Acetonitrile

[0348] AcOH acetic acid

[0349] AlMe3 trimethylaluminum

[0350] Bn benzyl

[0351] BOC or Boc tert-butyl carbamate

[0352] CDI 1,1'-Carbonyldiimidazole

[0353] Cy3P BF4 tricyclohexylphosphonium tetrafluoroborate

[0354] DCE dichloroethane

[0355] DCM dichloromethane

[0356] DDQ 2,3-Dichloro-5,6-dicyano-p-benzoquinone

[0357] DIPEA or DIEA diisopropylethylamine

[0358] DMAP 4-(N,N-dimethylamino)pyridine

[0359] DMF dimethylformamide

[0360] DMA N,N-dimethylacetamide

[0361] DMSO dimethyl sulfoxide

[0362] equiv equivalent

[0363] Et ethyl

[0364] EtOH

[0365] EA or EtOAc Ethyl acetate

[0366] HPLC high-performance liquid chromatography

[0367] LAH lithium aluminum hydride

[0368] Me methyl

[0369] MeOH methanol

[0370] MS

[0371] NMM N-Methylmorpholine

[0372] NMR Nuclear Magnetic Resonance

[0373] Pd(dppf)Cl2 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)

[0374] Pd(DTBPF)Cl2 [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II)

[0375] Pd(OAc)2 Palladium(II) acetate

[0376] PMB p-methoxybenzyl

[0377] TEA triethylamine

[0378] TFA trifluoroacetic acid

[0379] THF Tetrahydrofuran

[0380] Example 1: Synthesis of 5-(3-ethoxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 101)

[0381]

[0382] Step 1: To a stirred solution of 4-bromo-2-hydroxybenzonitrile (3.00 g, 15.2 mmol, 1.00 equiv) and KCO (4.19 g, 30.3 mmol, 2.00 equiv) in DMF (30.0 mL) was added iodoethane (3.07 g, 19.7 mmol, 1.30 equiv) at room temperature. The resulting mixture was stirred overnight. The resulting mixture was diluted with water (100 mL). The precipitated solid was collected by filtration and washed with water (2 x 20 mL). The resulting solid was dried under an infrared lamp. This gave 4-bromo-2-ethoxybenzonitrile (3 g, 88%) as an off-white solid.

[0383] Step 2: To a stirred mixture of NH4Cl (2.37 g, 44.2 mmol, 4.00 equiv) in toluene (20.0 mL) at room temperature under N2 atmosphere was added AlMe3 (22.1 mL, 44.2 mmol, 4.00 equiv) dropwise. The resulting mixture was stirred at room temperature for 30 min. To this mixture was added 4-bromo-2-ethoxybenzonitrile (2.50 g, 11.1 mmol, 1.00 equiv). The resulting mixture was stirred at 110°C for an additional 16 h. The mixture was allowed to cool to 0°C. The reaction was quenched by the dropwise addition of methanol (50 mL). The solid was filtered off, and the filter cake was washed with methanol (3 x 30 mL) and DCM (3 x 30 mL). The filtrate was concentrated under reduced pressure until a small amount of solvent remained. The residue was diluted with EA (30 mL), and the precipitated solid was collected by filtration and washed with EA (2 x 20 mL). The resulting solid was dried using an IR lamp. This resulted in 4-bromo-2-ethoxybenzimidamide hydrochloride (3 g, 97%) as a white solid. LCMS (ESI) = 243.1, 245.1 [M+H] + .

[0384] Step 3: To a stirred solution of MeOH (30 mL) at room temperature under N2 atmosphere was added portionwise Na (0.99 g, 42.9 mmol, 4.00 equiv). The resulting mixture was stirred at room temperature until the solid was completely dissolved. To the above mixture was added 4-bromo-2-ethoxybenzimidamide hydrochloride (3.00 g, 10.7 mmol, 1.00 equiv) and (E)-(cyano(hydroxyimino)carboxylic acid ethyl ester) (3.05 g, 21.5 mmol, 2.00 equiv). The resulting mixture was refluxed overnight. The mixture was allowed to cool to room temperature. The reaction was quenched by the addition of water (100 mL). The mixture was acidified to pH 5.0 with AcOH. The precipitated solid was collected by filtration and washed with water (3 x 20 mL). The resulting solid was dried using infrared irradiation. This resulted in 6-amino-2-(4-bromo-2-ethoxyphenyl)-5-nitroso-3H-pyrimidin-4-one (3 g, 82%) as a green solid. LCMS (ESI) = 338.8, 340.8 [M+H] + .

[0385] Step 4: To a stirred solution of 6-amino-2-(4-bromo-2-ethoxyphenyl)-5-nitroso-3H-pyrimidin-4-one (2.00 g, 5.90 mmol, 1.00 equiv) in water (20.0 mL) and TEA (4.00 mL) was added Na2S2O4 (3.08 g, 17.7 mmol, 3.00 equiv) at room temperature. The resulting mixture was stirred at room temperature for 30 min. The resulting mixture was diluted with water (20 mL). The mixture was acidified to pH 5.0 with AcOH. The precipitated solid was collected by filtration and washed with water (2 x 10 mL). The resulting solid was dried using infrared irradiation. This gave 5,6-diamino-2-(4-bromo-2-ethoxyphenyl)-3H-pyrimidin-4-one (1 g, 52%) as a green solid. LCMS (ESI) = 325.1, 327.1 [M+H] + .

[0386] Step 5: To a stirred solution of 5,6-diamino-2-(4-bromo-2-ethoxyphenyl)-3H-pyrimidin-4-one) in HCl (6M) (10.0 mL) was added sodium nitrite (0.42 g, 6.15 mmol, 2.00 equiv) in portions at 0 ° C. The resulting mixture was stirred at room temperature for 1 h. The resulting mixture was diluted with water (30 mL). The precipitated solid was collected by filtration and washed with water (2 x 10 mL). The crude product was purified by preparative HPLC to give 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (600 mg, 58%) as a white solid. LCMS (ESI) = 336.0, 337.9 [M+H] +. 1H NMR(300MHz,DMSO-d6)δ12.26(s,1H),7.63(d,J=8.2Hz,1H),7.41(d,J=1.7Hz, 1H), 7.30 (dd, J=8.3, 1.7Hz, 1H), 4.17 (q, J=6.9Hz, 2H), 1.32 (t, J=6.9Hz, 3H).

[0387] Step 6: Into an 8-mL sealed tube purged with nitrogen and maintained under an inert atmosphere of nitrogen was placed 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (30 mg, 1 equiv), phenylboronic acid (21.7 mg, 2 equiv), dioxane (0.5 mL), H2O (0.1 mL), K2CO3 (36.9 mg, 3 equiv), and Pd(dppf)Cl2 (6.5 mg, 0.1 equiv). The resulting solution was stirred in an oil bath at 100°C for 2 h. The solid was filtered off. The resulting mixture was concentrated under vacuum. The crude product was purified by preparative HPLC to give 5-(3-ethoxy-[1,1′-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 101) (12 mg, 40%) as a pale yellow solid. LCMS (ESI) = 334 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.24(s,1H),7.87(d,J=8.0Hz,1H),7.79(d,J=7.1Hz,2H),7. 52(t,J=7.3Hz,2H),7.44(q,J=7.5Hz,3H),4.31(q,J=6.9Hz,2H),1.40(t,J=6.9Hz,3H)

[0388] Example 2: Synthesis of 5-(2-ethoxy-4-(pyridin-3-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 102)

[0389]

[0390] 5-(2-Ethoxy-4-(pyridin-3-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 102) was prepared from 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one and pyridin-3-ylboronic acid using the procedure of Step 6 of Example 1. LCMS (ESI) = 335.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.34(s,1H),9.23(d,J=1.8Hz,1H),8.81(dd,J=5.2,1.3Hz,1H),8.64(d,J=8.0Hz,1H),7 .88(dd,J=8.0,3.6Hz,2H),7.61(s,1H),7.55(dd,J=8.0,1.5Hz,1H),4.32(q,J=7.0Hz,2H),1.39(t,J=6.9Hz,3H).

[0391] Example 3: Synthesis of 5-(2-ethoxy-4-(pyrimidin-2-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 103)

[0392]

[0393] 5-(2-Ethoxy-4-(pyrimidin-2-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared from 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one and 2-(tributylstannyl)pyrimidine using the procedure of Step 6 of Example 1. LCMS (ESI) = 336.1 [M+H] + .

[0394] Example 4: Synthesis of 5-(2-ethoxy-4-(pyridin-4-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 104)

[0395]

[0396] 5-(2-Ethoxy-4-(pyridin-4-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared from 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one and pyridin-4-ylboronic acid using the procedure of Step 6 of Example 1. LCMS (ESI) = 335.1 [M+H] + .

[0397] Example 5: Synthesis of 5-(2-ethoxy-4-(pyridin-2-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 105)

[0398]

[0399] 5-(2-Ethoxy-4-(pyridin-2-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared from 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one and 2-(tributylstannyl)pyridine using the procedure of Step 6 of Example 1. LCMS (ESI) = 335.1 [M+H] + .

[0400] Example 6: Synthesis of methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylate (Compound 106)

[0401]

[0402] Step 1: To a stirred solution of 1-(azidomethyl)-4-methoxybenzene (5.00 g, 30.6 mmol, 1.00 equiv) and cyanoacetamide (2.58 g, 30.6 mmol, 1.00 equiv) in EtOH (50.0 mL) was added EtONa (6.26 g, 91.9 mmol, 3.00 equiv) at room temperature under N2. The resulting mixture was stirred at 78 ° C for 3 h under N2. The mixture was allowed to cool to room temperature. The precipitated solid was collected by filtration and washed with EtOH (2 x 10 mL). The resulting solid was dried under an infrared lamp. This yielded 5-amino-1-[(4-methoxyphenyl)methyl]-1,2,3-triazole-4-carboxamide (3 g, 40%) as a gray solid.

[0403] Step 2: To a stirred solution of 4-bromo-2-hydroxybenzaldehyde (2.00 g, 9.949 mmol, 1.00 equiv) and KCO (2.75 g, 19.9 mmol, 2.00 equiv) in DMF (20.0 mL) was added iodoethane (1.86 g, 11.9 mmol, 1.20 equiv) at room temperature. The resulting mixture was stirred at room temperature overnight. The resulting mixture was diluted with water (100 mL). The precipitated solid was collected by filtration and washed with water (2 x 20 mL). The resulting solid was dried under an infrared lamp. This gave 4-bromo-2-ethoxybenzaldehyde (1.9 g, 83%) as a white solid.

[0404] Step 3: To a stirred solution of 5-amino-1-[(4-methoxyphenyl)methyl]-1,2,3-triazole-4-carboxamide (1.50 g, 6.07 mmol, 1.00 equiv) and 4-bromo-2-ethoxybenzaldehyde (2.08 g, 9.10 mmol, 1.50 equiv) in AcOH (20.0 mL) was added DDQ (2.75 g, 12.1 mmol, 2.00 equiv) at room temperature. The resulting mixture was stirred at 80°C for 24 h. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with water (50 mL). The precipitated solid was collected by filtration and washed with water (2 x 10 mL). The residue was redissolved with aqueous sodium bicarbonate (50 mL). The precipitated solid was collected by filtration and washed with aqueous sodium bicarbonate (2 x 10 mL) and water (2 x 10 mL). The resulting solid was dried under an infrared lamp. This resulted in 5-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 106-A) (1.5 g, crude) as a gray solid. The crude product (30 mg) was purified by preparative HPLC to give 5-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (7 mg) as a white solid. LCMS (ESI) = 456 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.44(s,1H),7.68(d,J=8.3Hz,1H),7.43(d,J=1.5Hz,1H),7.35(d,J=8.4Hz ,3H),6.92(d,J=8.7Hz,2H),5.69(s,2H),4.18(q,J=6.9Hz,2H),3.73(s,3H),1.32(t,J=6.9Hz,3H).

[0405] Step 4: To a stirred solution of 5-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (100 mg, 0.219 mmol, 1.00 equiv), 2-(methoxycarbonyl)phenylboronic acid (78.9 mg, 0.438 mmol, 2.00 equiv), and KCO (90.86 mg, 0.657 mmol, 3.00 equiv) in dioxane / HO (2 / 0.20 mL) was added Pd(dppf)Cl CHCl (17.9 mg, 0.022 mmol, 0.10 equiv) at room temperature under N2 atmosphere. The resulting mixture was stirred at 100°C overnight. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The resulting mixture was diluted with water (2 mL). The precipitated solid was collected by filtration and washed with water (2x2mL). The resulting solid was dried under an infrared lamp. This produced 3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-methylformate (100 mg, 89%) as a gray solid.

[0406] Step 5: A solution of 3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester (100 mg, 0.195 mmol, 1 equiv) in 2,2,2-trifluoroacetaldehyde (1 mL) was stirred at 80 ° C for 2 h. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with water (5 mL). The precipitated solid was collected by filtration and washed with water (2x1 mL). The resulting solid was dried with infrared light. This produced 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester (90 mg, crude) as a gray solid. The crude product (20 mg) was purified by preparative HPLC to give methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylate (5 mg, 6%) as a white solid. LCMS (ESI) = 392.1 [M+H] + . 1H NMR (300MHz, DMSO-d6) δ12.03(s,1H),8.14(s,1H),7.85(d,J=7.9Hz,1H),7.79(d,J=7.7Hz,1H),7.68(t,J=7.6Hz,1H) ,7.55(t,J=7.4Hz,2H),7.09(s,1H),7.02(d,J=8.0Hz,1H),4.20(q,J=6.7Hz,2H),3.66(s,3H),1.38(t,J=6.9Hz,3H).

[0407] Example 7: Synthesis of methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate (Compound 107)

[0408]

[0409] The procedure of Steps 4 and 5 of Example 6 was used to prepare methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate, except that (3-(methoxycarbonyl)phenyl)boronic acid was used in Step 4. LCMS (ESI) = 392.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.22(s,1H),8.28(s,1H),8.06(dd,J=17.6,7.8Hz,2H),7.90(d,J=7.9Hz,1H),7 .69(t,J=7.8Hz,1H),7.52–7.41(m,1.8Hz,2H),4.32(q,J=6.9Hz,2H),3.92(s,3H),1.40(t,J=6.9Hz,3H).

[0410] Example 8: Synthesis of methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylate (Compound 108)

[0411]

[0412] The procedure of Example 6, Steps 4 and 5 was used to prepare methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylate, except that (4-(methoxycarbonyl)phenyl)boronic acid was used in Step 4. LCMS (ESI) = 392.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.26(s,1H),8.09(d,J=8.5Hz,2H),7.96(d,J=8.5Hz,2H),7.89(d, J=7.9Hz,1H),7.56–7.45(m,2H),4.32(q,J=7.1Hz,2H),3.90(s,3H),1.40(t,J=6.9Hz,3H).

[0413] Example 9: Synthesis of 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylic acid (Compound 109)

[0414]

[0415] To a stirred solution of methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylate (70.0 mg, 0.179 mmol, 1.00 equiv) in MeOH / H2O (2 / 0.4 mL) was added NaOH (35.8 mg, 0.894 mmol, 5.00 equiv) at room temperature. The resulting mixture was stirred overnight. The resulting mixture was diluted with water (10 mL). The aqueous layer was extracted with EA (2 x 5 mL). The mixture was acidified to pH 3-4 with concentrated HCl. The resulting mixture was extracted with EA (3 x 5 mL). The combined organic layers were washed with brine (1 x 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylic acid (Compound 109) (20.5 mg, 30%) as a white solid. LCMS (ESI) = 378.1 [M+H] + . 1H NMR (300MHz, DMSO-d6) δ12.23(s,1H),7.90–7.73(m,J=13.7,4.6Hz,2H),7.69–7.57(m,J=7.5,1.4Hz,1H),7.57 –7.42(m,2H),7.15(d,J=1.2Hz,1H),7.07(dd,J=8.0,1.4Hz,1H),4.21(q,J=6.9Hz,2H),1.37(t,J=6.9Hz,3H).

[0416] Example 10: Synthesis of 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 110)

[0417]

[0418] 3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 110) was prepared from Compound 107 using the procedure of Example 9. LCMS (ESI) = 378.1 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ12.20(s,1H),8.27(s,1H),8.09–7.97(m,2H),7.90(d,J=7.9Hz,1 H),7.66(t,J=7.8Hz,1H),7.52–7.40(m,2H),4.33(q,J=6.9Hz,2H),1.40(t,J=6.9Hz,3H).

[0419] Example 11: Synthesis of 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 111 Palladium(II) acetate)

[0420]

[0421] 3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 111) was prepared from Compound 108 using the procedure of Example 9. LCMS (ESI) = 378.1 [M+H] + . 1H NMR (300MHz, DMSO-d6) δ12.04(s,1H),8.06(d,J=8.4Hz,2H),7.99–7.87(m,3H),7.56–7.43(m,2H),4.32(q,J=6.8Hz,2H),1.40(t,J=6.9Hz,3H).

[0422] Example 12: Synthesis of methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinate (Compound 112)

[0423]

[0424] Methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinate (Compound 112) was prepared using the procedure of Example 6, Steps 4 and 5, except using (5-(methoxycarbonyl)pyridin-3-yl)boronic acid in Step 4. LCMS (ESI) = 393.2 [M+H] + .

[0425] Example 13: Synthesis of 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinic acid (Compound 113)

[0426]

[0427] 5-(3-Ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinic acid (Compound 113) was prepared from Compound 112 using the procedure of Example 9.

[0428] Example 14: Synthesis of methyl 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)acetate (Compound 114)

[0429]

[0430] Methyl 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)acetate (Compound 114) was prepared using the procedure of Example 6, Steps 4 and 5, except using (4-(2-methoxy-2-oxoethyl)phenyl)boronic acid in Step 4. LCMS (ESI) = 406.2 [M+H] + .

[0431] Example 15: Synthesis of 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 115)

[0432]

[0433] 2-(3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 115) was prepared from Compound 114 using the procedure of Example 9. LCMS (ESI) = 392.1 [M+H] + .

[0434] Example 16: Synthesis of methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)thiophene-2-carboxylate (Compound 116)

[0435]

[0436] Methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)thiophene-2-carboxylate (Compound 116) was prepared using the procedure of Example 6, Steps 4 and 5, except using methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylate in Step 4. LCMS (ESI) = 398.1 [M+H] + .

[0437] Example 17: Synthesis of 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)thiophene-2-carboxylic acid (Compound 117)

[0438]

[0439] 5-(3-Ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)thiophene-2-carboxylic acid (Compound 117) was prepared from Compound 116 using the procedure of Example 9. LCMS (ESI) = 384.1 [M+H] + .

[0440] Example 18: Synthesis of methyl 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-yl)acetate (Compound 118)

[0441]

[0442] Methyl 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-yl)acetate (Compound 118) was prepared using the procedure of Example 6, Steps 4 and 5, except using (2-(2-methoxy-2-oxoethyl)phenyl)boronic acid in Step 4. LCMS (ESI) = 406.2 [M+H] + .

[0443] Example 19: Synthesis of 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-yl)acetic acid (Compound 119)

[0444]

[0445] 2-(3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-yl)acetic acid (Compound 119) was prepared from Compound 118 using the procedure of Example 9. LCMS (ESI) = 392.2 [M+H] + .

[0446] Example 20: Synthesis of ethyl 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (Compound 120)

[0447]

[0448] Ethyl 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (Compound 120) was prepared using the procedure of Example 6, Steps 4 and 5, except using ethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate in Step 4. LCMS (ESI) = 436.2 [M+H] + .

[0449] Example 21: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (Compound 121)

[0450]

[0451] 2-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (Compound 121) was prepared from Compound 120 using the procedure of Example 9. LCMS (ESI) = 408.2 [M+H] + .

[0452] Example 22: Synthesis of 5-amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid methyl ester (Compound 122)

[0453]

[0454] The procedure of Steps 4 and 5 of Example 6 was used to prepare methyl 5-amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate, except that (3-amino-5-(methoxycarbonyl)phenyl)borate hydrochloride was used in Step 4. LCMS (ESI) = 407.2 [M+H] + .

[0455] Example 23: Synthesis of 5-amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 123)

[0456]

[0457] 5-Amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 123) was prepared from Compound 122 using the procedure of Example 9. LCMS (ESI) = 393.1 [M+H] + .

[0458] Example 24: Synthesis of methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinate (Compound 124)

[0459]

[0460] Methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinate (Compound 124) was prepared using the procedure of Example 6, Steps 4 and 5, except using (6-(methoxycarbonyl)pyridin-3-yl)boronic acid in Step 4. LCMS (ESI) = 393.1 [M+H] + .

[0461] Example 25: Synthesis of 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinic acid (Compound 125)

[0462]

[0463] 5-(3-Ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinic acid (Compound 125) was prepared from Compound 124 using the procedure of Example 9. LCMS (ESI) = 379.1 [M+H] + .

[0464] Example 26: Synthesis of ethyl 2-(4-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-1H-pyrazol-1-yl)acetate (Compound 126)

[0465]

[0466] Ethyl 2-(4-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-1H-pyrazol-1-yl)acetate (Compound 126) was prepared using the procedure of Example 6, Steps 4 and 5, except using ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate in Step 4. LCMS (ESI) = 410.2 [M+H] + .

[0467] Example 27: Synthesis of 2-(4-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-1H-pyrazol-1-yl)acetic acid (Compound 127)

[0468]

[0469] 2-(4-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-1H-pyrazol-1-yl)acetic acid was prepared from compound 126 using the procedure of Example 9. LCMS (ESI) = 382.2 [M+H] + .

[0470] Example 28: Synthesis of 4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-propoxy-[1,1'-biphenyl]-3-carboxylic acid (Compound 128)

[0471]

[0472] 4'-(7-Oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-propoxy-[1,1'-biphenyl]-3-carboxylic acid was prepared using the procedure in Example 6, except that 1-iodopropane was used in step 2. LCMS (ESI) = 392.1 [M+H] + .

[0473] Example 29: Synthesis of 5-([1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 129)

[0474]

[0475] 5-([1,1′-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure in Example 6, except that 4-bromobenzaldehyde was used in step 3. LCMS (ESI) = 290.1 ​​[M+H] + .

[0476] Example 30: Synthesis of 5-(4-cyclopropyl-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 130)

[0477]

[0478] Step 1: To a stirred solution of 5-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 106-A) (50.0 mg, 0.110 mmol, 1.00 equiv), K3PO4 (69.8 mg, 0.329 mmol, 3.00 equiv) and cyclopropylboronic acid (18.8 mg, 0.219 mmol, 2.00 equiv) in toluene / water (1 / 0.10 mL) was added tricyclohexylphosphonium tetrafluoroborate (8.07 mg, 0.022 mmol, 0.20 equiv) and Pd(OAc)2 (2.46 mg, 0.011 mmol, 0.10 equiv) at room temperature under N2 atmosphere. The resulting mixture was stirred at 100°C overnight. The mixture was allowed to cool to room temperature. The residue was purified by silica gel column chromatography to give 5-(4-cyclopropyl-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (36 mg, 79%) as an off-white solid. LCMS (ESI) = 418.2 [M+H] + .

[0479] Step 2: To an 8 mL vessel was added 5-(4-cyclopropyl-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (36.00 mg, 0.086 mmol, 1.00 equiv) and 2,2,2-trifluoroacetaldehyde (1.00 mL) at room temperature. The resulting mixture was stirred at 80 ° C for 1.5 h. The resulting mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give 5-(4-cyclopropyl-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 130) (9.5 mg, 32%) as a white solid. LCMS (ESI) = 298.1 [M+H] + . 1 HNMR (300MHz, DMSO-d6): δ11.12(s,1H),8.22(s,1H),7.84(d,J=8.1Hz,1H),6.88(d,J=1.2Hz,1H),6.78(dd,J=8.1 ,1.4Hz,1H),4.20(q,J=7.0Hz,2H),2.06–1.92(m,1H),1.39(t,J=6.9Hz,3H),1.09–0.93(m,2H),0.86–0.71(m,2H).

[0480] Example 31: Synthesis of 5-(2-ethoxy-4-(1H-pyrazol-3-yl)phenyl)-1,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 131)

[0481]

[0482] 5-(2-Ethoxy-4-(1H-pyrazol-3-yl)phenyl)-1,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure of Example 6, Steps 4 and 5, except that (1H-pyrazol-3-yl)boronic acid was used in Step 4. LCMS (ESI) = 324.1 [M+H] + .

[0483] Example 32: Synthesis of 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoic acid (Compound 132)

[0484]

[0485] Step 1: To a 30 mL pressure tank reactor was added 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 101-A) (50 mg, 0.149 mmol, 1 equiv), Pd(dppf)Cl2 (10.9 mg, 0.015 mmol, 0.1 equiv), and triethylamine (45.2 mg, 0.446 mmol, 3 equiv) in MeOH at room temperature. The mixture was stirred at 120°C under 10 atm of CO atmosphere for 3 h. The resulting mixture was concentrated under reduced pressure. The crude product (40 mg) was used in the next step without further purification. To obtain an analytical sample, the crude product (20 mg) was purified by preparative HPLC to give methyl 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoate (Compound 132-A) (14.1 mg, 26%) as a white solid. LCMS (ESI) = 316.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.47(s,1H),7.81(d,J=8.0Hz,1H),7.76–7.55(m,2H),4.21(q,J=6.9Hz,2H),3.91(s,3H),1.34(t,J=6.9Hz,3H).

[0486] Step 2: To an 8 mL vial was added methyl 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoate (30 mg, 0.09 mmol, 1 equiv) and NaOH (11.4 mg, 0.28 mmol, 3 equiv) in MeOH / H2O (1 mL / 0.2 mL), and the solution was stirred at room temperature for 2 h. The resulting mixture was filtered, and the filter cake was washed with EtOAc (3 x 5 mL). The filtrate was concentrated under reduced pressure. The residue was dissolved in DMSO (3 mL) and purified by preparative chromatography to give 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoic acid (Compound 132) (8.5 mg) as an off-white solid. LCMS (ESI) = 302.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.00 (s, 1H), 7.83 (d, J = 7.8Hz, 1H), 7.64 (d, J = 10.4Hz, 2H), 4.21 (q, J = 6.9Hz, 2H), 1.36 (t, J = 6.9Hz, 3H).

[0487] Example 33: Synthesis of 5-(2-ethoxy-4-(pyrrolidine-1-carbonyl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 133)

[0488]

[0489] To a stirred solution of 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoic acid (50 mg, 0.166 mmol, 1 equiv) and DIEA (64.4 mg, 0.498 mmol, 3.0 equiv) in DMF (1 mL) was added HATU (75.7 mg, 0.199 mmol, 1.2 equiv). Pyrrolidine (23.6 mg, 0.332 mmol, 2 equiv) was added to the above mixture at room temperature. The resulting mixture was stirred at room temperature overnight. The crude product was purified by preparative HPLC to give 5-(2-ethoxy-4-(pyrrolidine-1-carbonyl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (5.1 mg, 8%) as a white solid. LCMS (ESI) = 355.4 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.32(s,1H),7.75(d,J=7.8Hz,1H),7.26(s,1H),7.20(d,J=7.9Hz,1H),4.24 –4.12(m,2H),3.49(t,J=6.0Hz,2H),3.41(t,J=5.8Hz,2H),1.95–1.79(m,4H),1.34(t,J=6.9Hz,3H).

[0490] Example 34: Synthesis of 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-N-phenylbenzamide (Compound 134)

[0491]

[0492] 3-Ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-N-phenylbenzamide (Compound 134) was prepared using the procedure in Example 33, except that aniline was used in the amide coupling step. LCMS (ESI) = 377.1 [M+H] + . 1H NMR (300MHz, DMSO-d6) δ12.30(s,1H),10.37(s,1H),7.86(d,J=7.5Hz,1H),7.79(d,J=7.7Hz,2H),7.73– 7.65(m,2H),7.39(t,J=7.9Hz,2H),7.14(t,J=7.4Hz,1H),4.27(q,J=6.9Hz,2H),1.38(t,J=6.8Hz,3H).

[0493] Example 35: Synthesis of 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzamide (Compound 135)

[0494]

[0495] 3-Ethoxy-4-(7-oxo-6,7-dihydro-1H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzamide (Compound 135) was prepared using the procedure in Example 33, except that ammonium carbonate was used in the amide coupling step. LCMS (ESI) = 301.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.33(s,1H),8.15(s,1H),7.76(d,J=7.8Hz,1H),7.66–7.50(m,3H),4.21(q,J=7.1Hz,2H),1.36(t,J=6.9Hz,3H).

[0496] Example 36: Synthesis of N-cyclopentyl-3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzamide (Compound 136)

[0497]

[0498] To an 8 mL vial was added methyl 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoate (50.0 mg, 0.159 mmol, 1.00 equiv) and cyclopentylamine (67.5 mg, 0.793 mmol, 5.00 equiv) at room temperature. The resulting mixture was stirred at 100 ° C overnight. The mixture was allowed to cool to room temperature. The resulting mixture was diluted with DMSO (3 mL). The mixture was purified by preparative HPLC to give N-cyclopentyl-3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzamide (9.7 mg, 17%) as a white solid. LCMS (ESI) = 369.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6): δ12.26(s,1H),8.43(d,J=7.1Hz,1H),7.79(d,J=8.4Hz,1H),7.64–7 .52(m,2H),4.34–4.14(m,3H),2.03–1.84(m,2H),1.82–1.47(m,6H),1.37(t,J=6.9Hz,3H).

[0499] The following compounds (Compounds 137-192) were prepared using methods similar to those described in Examples 1-36.

[0500]

[0501]

[0502]

[0503]

[0504]

[0505]

[0506]

[0507]

[0508] Example 37: Synthesis of (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylate (Compound 193)

[0509]

[0510] To an 8 mL vial was added 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (50.0 mg, 0.132 mmol, 1.0 equiv), HATU (61.0 mg, 0.160 mmol, 1.2 equiv), and DIEA (52.0 mg, 0.402 mmol, 3.0 equiv) in DMF (1.00 mL). 4-(Hydroxymethyl)-5-methyl-1,3-dioxol-2-one (35.0 mg, 0.269 mmol, 2.0 equiv) was added at room temperature and the mixture was stirred for 6 h. The crude reaction (4 mL) was purified by preparative HPLC to give (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylate (25.1 mg, 37%) as an off-white solid. LCMS (ESI) = 490.2 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ11.81(s,1H),8.18–8.04(m,2H),8.02–7.89(m,3H),7.48(d, J=7.2Hz,2H),5.27(s,2H),4.32(q,J=6.9Hz,2H),2.25(s,3H),1.41(t,J=6.9Hz,3H).

[0511] Example 38: Synthesis of 3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 194)

[0512]

[0513] 3'-(Cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedures in Examples 6 and 9, except that bromocyclopentane was used in Step 2 of Example 6. LCMS (ESI) = 418.1 [M+H] + . 1H NMR(300MHz,DMSO-d6)δ8.08(dd,J=12.9,8.1Hz,3H),7.89(d,J=8.1Hz,2H),7 .46(d,J=8.1Hz,2H),5.28–5.19(m,1H),2.09–1.82(m,4H),1.82–1.53(m,4H).

[0514] Example 39: Synthesis of 2'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 195)

[0515]

[0516] 2'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedures in Examples 6 and 9. LCMS (ESI) = 378.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.98(d,J=8.0Hz,2H),7.84(d,J=7.8Hz,2H),7.66(d,J= 8.0Hz, 2H), 7.46 (d, J = 8.1Hz, 1H), 4.23 (q, J = 6.9Hz, 2H), 1.34 (t, J = 6.9Hz, 3H).

[0517] Example 40: Synthesis of 2',6'-dimethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 196)

[0518]

[0519] 2',6'-Dimethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedures in Examples 6 and 9. LCMS (ESI) = 394.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.96 (d, J = 8.2 Hz, 2H), 7.57 (s, 2H), 7.40 (d, J = 8.3 Hz, 2H), 3.81 (s, 6H).

[0520] Example 41: Synthesis of 5-(3'-amino-3-ethoxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 197)

[0521]

[0522] 5-(3'-Amino-3-ethoxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure in Example 6. LCMS (ESI) = 349.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6): δ11.97(s,1H),7.88(d,J=8.5Hz,1H),7.30(d,J=6.6Hz,2H),7.14(t,J=7.8Hz,1H),6 .94(t,J=1.9Hz,1H),6.89(d,J=7.6Hz,1H),6.71–6.58(m,1H),4.28(q,J=6.9Hz,2H),1.41(t,J=6.9Hz,3H).

[0523] Example 42: Synthesis of 3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 198)

[0524]

[0525] Step 1: To a 40 mL vial was added 5-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (1.00 g, 2.19 mmol, 1.0 equiv) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bis(1,3,2-dioxaborolane) (1.11 g, 4.37 mmol, 2.0 equiv) in 1,4-dioxane (10 mL) at room temperature under N2, along with KOAc (645 mg, 6.57 mmol, 3.0 equiv) and Pd(dppf)Cl2 (160 mg, 0.219 mmol, 0.10 equiv). The resulting mixture was stirred at 100 ° C for 2h, and then the reaction was quenched by adding water (100mL) at room temperature. The precipitated solid was collected by filtration and washed with water (2x10mL) and petroleum ether (2x10mL) and dried to give 5- (2-ethoxy-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) -3- (4-methoxybenzyl) -3,6-dihydro -7H- [1,2,3] triazolo [4,5-d] pyrimidin-7-one (1.3g, crude product) as a brown solid. LCMS (ESI) = 502.2 [M + H] + .

[0526] Step 2: To an 8 mL vial was added 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (50.0 mg, 0.099 mmol, 1.0 equiv), 3-bromo-5-hydroxybenzoic acid (32.0 mg, 0.147 mmol, 1.5 equiv), KCO (41.0 mg, 0.297 mmol, 3.0 equiv), Pd(dppf)Cl (10 mg, 0.014 mmol, 0.14 equiv), dioxane (1.0 mL), and H0 (0.10 mL). The resulting mixture was heated at 80° C. under N for 2 h and then allowed to cool to room temperature. The mixture was acidified to pH 4 with HCl (aqueous solution), and the precipitated solid was collected by filtration to give 3'-ethoxy-5-hydroxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (53 mg) as a brown solid. LCMS (ESI) = 514.2 [M+H] + .

[0527] Step 3: To a vial was added 3'-ethoxy-5-hydroxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (53.0 mg, 0.103 mmol, 1.0 equiv) and trifluoroacetic acid (2.0 mL). The resulting mixture was stirred at 80 °C for 2 h. The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by preparative HPLC to give 3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (6.3 mg, 16%) as an off-white solid. LCMS (ESI) = 394.1 [M+H] + LCMS (ESI) = 394.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.00(s,1H),10.00(s,1H),7.90(d,J=8.2Hz,1H),7.71(s,1H),7.44–7.33(m,4H),4.31(q,J=6.8Hz,2H).

[0528] Example 43: Synthesis of 3'-(cyclopentyloxy)-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 199)

[0529]

[0530] 3'-(Cyclopentyloxy)-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was prepared using the procedures in Examples 6 and 42, except that bromocyclopentane was used in Step 2 of Example 6. LCMS (ESI) = 434.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ10.01(s,1H),7.96(d,J=8.2Hz,1H),7.70(s,1H),7.38(t,J=7.5Hz,4H),2.04–1.78(m,4H),1.67–1.61(m,4H).

[0531] Example 44: Synthesis of 3'-(cyclopentyloxy)-4-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 200)

[0532]

[0533] 3'-(Cyclopentyloxy)-4-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was prepared using the procedure in Example 42. LCMS (ESI) = 434.1 [M+H] + . 1 HNMR(300MHz,DMSO-d6)δ12.02(s,1H),8.12(d,J=2.5Hz,1H),8.00–7.86(m,2H),7.46– 7.33(m,2H),7.08(d,J=8.5Hz,1H),5.22(s,1H),2.16–1.74(m,4H),1.76–1.47(m,4H).

[0534] Example 45: Synthesis of 3'-(cyclopentyloxy)-3-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 201)

[0535]

[0536] 3'-(Cyclopentyloxy)-3-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure in Example 42. LCMS (ESI) = 434.1 [M+H] + . 1 HNMR(300MHz,DMSO-d6)δ7.99(d,J=8.3Hz,1H),7.80(d,J=8.0Hz,1H),7.43–7.33(m,2H), 7.12–7.01(m,2H),5.18(s,1H),1.97–1.91(m,2H),1.87–1.81(m,2H),1.67–1.61(m,4H).

[0537] Example 46: Synthesis of 3'-(cyclopentyloxy)-2-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 202)

[0538]

[0539] 3'-(Cyclopentyloxy)-2-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure in Example 42. LCMS (ESI) = 434.2 [M+H] + . 1 HNMR (300MHz, DMSO-d6) δ12.10 (s, 1H), 7.91 (dd, J = 8.2, 5.7Hz, 2H), 7.47 (s, 2H), 7. 38–7.26(m,2H),5.23(tt,J=5.7,2.7Hz,1H),2.04–1.77(m,4H),1.75–1.55(m,4H).

[0540] Example 47: Synthesis of 5-(3-ethoxy-3',5'-difluoro-4'-hydroxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 203)

[0541]

[0542] 5-(3-Ethoxy-3',5'-difluoro-4'-hydroxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure in Example 42. LCMS (ESI) = 386.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ11.95 (s, 1H), 7.91–7.82 (m, 1H), 7.59 (dd, J = 8.3, 1. 7Hz, 2H), 7.42 (d, J = 6.8Hz, 2H), 4.32 (q, J = 6.9Hz, 2H), 1.40 (t, J = 6.9Hz, 3H).

[0543] Example 48: Synthesis of 3-amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 204)

[0544]

[0545] 3-Amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure in Example 42, except that Pd(DTBPF)Cl2 was used in step 2. LCMS (ESI) = 392.4 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.92(d,J=8.5Hz,1H),7.81(d,J=8.3Hz,1H),7.35(d,J=6.8Hz,2H),7. 14(d,J=1.8Hz,1H), 6.92(dd,J=8.4,1.8Hz,1H), 4.29(q,J=6.9Hz,2H), 1.41(t,J=6.9Hz,3H).

[0546] Example 49: Synthesis of 3'-ethoxy-3-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 205)

[0547]

[0548] 3'-Ethoxy-3-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure in Example 48. LCMS (ESI) = 396.1 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ7.99(d,J=8.5Hz,1H),7.88(t,J=8.1Hz,1H),7.75–7 .63(m,2H),7.52–7.44(m,2H),4.34(q,J=6.9Hz,2H),1.42(t,J=6.9Hz,3H).

[0549] Example 50: Synthesis of 3'-ethoxy-3-methoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 206)

[0550]

[0551] 3'-Ethoxy-3-methoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure in Example 48. LCMS (ESI) = 408.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ8.00(d,J=8.0Hz,2H),7.75(d,J=7.8Hz,2H),7.48(dd,J=9.6,1.5Hz,4H ), 7.42 (s, 3H), 7.38 (d, J = 1.5Hz, 1H), 4.34 (q, J = 6.9Hz, 4H), 3.96 (s, 6H), 1.43 (t, J = 6.9Hz, 6H).

[0552] Example 51: Synthesis of 3'-ethoxy-3-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 207)

[0553]

[0554] 3'-Ethoxy-3-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure in Example 48. LCMS (ESI) = 392.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.89(s,1H),7.95(d,J=8.3Hz,1H),7.87(d,J=7.8Hz,1H),7.78–7. 67(m,2H),7.47(d,J=8.2Hz,2H),4.31(t,J=7.0Hz,2H),2.64(s,3H),1.40(t,J=7.0Hz,3H).

[0555] Example 52: Synthesis of 3'-ethoxy-3-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 208)

[0556]

[0557] 3'-Ethoxy-3-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared from methyl 4-bromo-2-hydroxybenzoate using the procedures in Examples 48 and 9. LCMS (ESI) = 394.01 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.87(d,J=8.4Hz,1H),7.74(d,J=7.8Hz,1H),7.37(d,J= 6.5Hz, 2H), 6.99 (d, J = 10.9Hz, 2H), 4.31 (q, J = 6.9Hz, 2H), 1.39 (t, J = 6.9Hz, 3H).

[0558] Example 53: Synthesis of 3'-(cyclopentyloxy)-2-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 209)

[0559]

[0560] 3'-(Cyclopentyloxy)-2-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was prepared from methyl 3-bromo-2-hydroxybenzoate using the procedures in Examples 42 and 9. LCMS (ESI) = 434.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.06(s,1H),7.90(t,J=9.2Hz,2H),7.65(d,J=7.6Hz,1H),7.45(s,1H ),7.38–7.23(m,1H),7.01(t,J=7.8Hz,1H),5.06(s,1H),2.09–1.80(m,4H),1.60-1.80(m,4H).

[0561] Example 54: Synthesis of 3'-(cyclopentyloxy)-6-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 210)

[0562]

[0563] 3'-(Cyclopentyloxy)-6-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was prepared from methyl 3-bromo-4-hydroxybenzoate using the procedures in Examples 42 and 9. LCMS (ESI) = 434.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ10.63(s,1H),7.99(d,J=8.2Hz,1H),7.93(d,J=2.2Hz,1H),7.83(dd,J=8.5,2.2Hz,1H),7.39(d,J= 1.6Hz,1H),7.28(dd,J=8.1,1.5Hz,1H),7.06(d,J=8.4Hz,1H),5.06(d,J=3.5Hz,1H),1.80-2.00(m,4H),1.80–1.51(m,4H).

[0564] Example 55: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)oxy)acetic acid (Compound 211)

[0565]

[0566] Step 1: To a 40 mL vial was added 4-bromophenol (1.00 g, 5.78 mmol, 1.0 equiv) and DMF (10 mL). Potassium carbonate (420 mg, 17.5 mmol, 3.0 equiv) was added portionwise to the above mixture at 0°C. The resulting mixture was stirred at 0°C for another 30 min. 2-bromoacetic acid tert-butyl ester (1.40 g, 7.18 mmol, 1.24 equiv) was added to the above mixture. The resulting mixture was stirred at room temperature until TLC analysis showed that the starting material was consumed. The resulting mixture was diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (3 x 100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. This gave tert-butyl 2-(4-bromophenoxy)acetate (1.1 g, 66%) as a colorless oil.

[0567] Step 2: To a 40 mL vial was added tert-butyl 2-(4-bromophenoxy)acetate (300 mg, 1.04 mmol, 1.0 equiv), bis(pinacolato)diboron (293 mg, 1.15 mmol, 1.1 equiv), Pd(dppf)Cl2 (60.0 mg, 0.082 mmol, 0.08 equiv), KOAc (308 mg, 3.14 mmol, 3.0 equiv) and dioxane (5.0 mL). The resulting mixture was stirred at 80 ° C. under N2 for 4 h. The residue was purified by silica gel column chromatography to give tert-butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate (240 mg, 69%) as a colorless oil. LCMS (ESI) = 333.2 [MH] + .

[0568] Step 3: To an 8 mL vial was added tert-butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate (80 mg, 0.239 mmol, 1.0 equiv), 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (120 mg, 0.36 mmol, 1.5 equiv), KCO (99.0 mg, 0.716 mmol, 3.0 equiv), Pd(dppf)Cl (16.0 mg, 0.022 mmol, 0.09 equiv), dioxane (2.0 mL), and H0 (0.20 mL). The resulting mixture was stirred at 100° C. under N for 16 h. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford tert-butyl 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)oxy)acetate (75 mg, 68%) as an off-white solid.

[0569] Step 4: To a 50 mL round-bottom flask was added tert-butyl 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)oxy)acetate (75.0 mg, 0.162 mmol, 1.0 equiv) and 1 M HCl / EtOAc (10 mL). The resulting mixture was stirred at 50 °C for 16 h. The crude product was purified by preparative HPLC to give 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)oxy)acetic acid (19.6 mg, 30%) as an off-white solid. LCMS (ESI) = 408.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.06(s,1H),7.88(d,J=8.3Hz,1H),7.74(d,J=8.7Hz,2H),7.38 (m, 2H), 7.05 (d, J = 8.7Hz, 2H), 4.75 (s, 2H), 4.31 (q, J = 6.9Hz, 2H), 1.40 (t, J = 6.9Hz, 3H).

[0570] Example 56: Synthesis of (±)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 212)

[0571]

[0572] To a stirred solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.00 g, 4.54 mmol, 1.0 equiv) and methyl 2-bromopropionate (1.14 g, 6.82 mmol, 1.5 equiv) in DMF (10.0 mL) was added KCO (1.26 g, 9.09 mmol, 2.0 equiv) at room temperature. The resulting mixture was stirred at 60 ° C for 16 h, then the mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl 2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propanoate (520 mg, 37%) as a white solid.

[0573] 2-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedures in Examples 1 and 9. LCMS (ESI) = 422.1 [M+H] + . 1 HNMR (300MHz, DMSO-d6) δ8.00(d,J=8.5Hz,1H),7.39–7.25(m,3H),7.25–7.12(m,2H),6.82(d,J=8.0Hz,1H),4.45–4.25(m,3H),1.47–1.36(m,6H).

[0574] Example 57: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-2-methylpropanoic acid (Compound 213)

[0575]

[0576] 2-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-2-methylpropanoic acid was prepared using the procedures in Examples 56, 1, and 9. LCMS (ESI) = 436.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6): δ7.96 (d, J=8.5Hz, 1H), 7.41–7.28 (m, 4H), 7.20 (s, 1H), 6.89 (d, J=7.1Hz, 1H), 4.31 (q, J=6.9Hz, 2H), 1.55 (s, 5H), 1.42 (t, J=6.9Hz, 3H).

[0577] Example 58: Synthesis of (3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (Compound 214)

[0578]

[0579] Step 1: To a 40 mL vial was added tert-butyl N-(3-bromophenyl)carbamate (1.00 g, 3.68 mmol, 1.0 equiv), tert-butyl 2-bromoacetate (1.07 g, 5.51 mmol, 1.5 equiv), NaH (220 mg, 5.51 mmol, 1.5 equiv, 60%), and DMF (10.0 mL) at room temperature. The mixture was stirred for 1 h, and then the reaction was quenched with ice water (50 mL). The resulting mixture was extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (1 x 20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give tert-butyl N-(3-bromophenyl)-N-(tert-butoxycarbonyl)glycate (800 mg, 56%) as a colorless oil. LCMS (ESI) = 372 [M+H] + .

[0580] Step 2: To an 8 mL vial was added tert-butyl N-(3-bromophenyl)-N-(tert-butoxycarbonyl)glycine ester (300 mg, 0.777 mmol, 1.0 equiv), bis(pinacolato)diboron (296 mg, 1.16 mmol, 1.5 equiv), Pd(dppf)Cl2 (56.8 mg, 0.078 mmol, 0.10 equiv), KOAc (229 mg, 2.33 mmol, 3.0 equiv), and dioxane (5 mL). The mixture was stirred at 100 ° C for 2 h. The resulting mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give tert-butyl N-(tert-butoxycarbonyl)-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)glycine ester (270 mg, 80%) as a colorless oil.

[0581] Step 3: To an 8 mL vial was added 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (70.0 mg, 0.208 mmol, 1.0 equiv), N-(tert-butyloxycarbonyl)-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)glycine tert-butyl ester (135 mg, 0.312 mmol, 1.5 equiv), K2CO3 (57.6 mg, 0.416 mmol, 2.0 equiv), Pd(dppf)Cl2 (15.2 mg, 0.021 mmol, 0.1 equiv), dioxane (1 mL) and H2O (0.3 mL). The resulting mixture was stirred at 100°C for 16 h. The mixture was allowed to cool to room temperature and acidified with 2M HCl to pH 6-7. The mixture was purified by silica gel column chromatography to give tert-butyl N-(tert-butoxycarbonyl)-N-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine as an off-white solid (50 mg, 43%).

[0582] Step 4: To an 8 mL vial was added tert-butyl N-(tert-butyloxycarbonyl)-N-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine ester (50.0 mg, 0.089 mmol, 1.0 equiv) and TFA (1.0 mL) at room temperature. The resulting mixture was stirred at room temperature for 2 h. The resulting mixture was concentrated under reduced pressure. The resulting mixture was diluted with DMSO (2 mL) and then purified by preparative HPLC to give (3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (9.1 mg, 25%) as a white solid. LCMS (ESI) = 407.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.95(d,J=8.4Hz,1H),7.32(dd,J=4.4,2.8Hz,2H),7.21(t,J=7.8Hz,1H),6. 95 (d, J = 9.1 Hz, 2H), 6.62 (d, J = 8.5 Hz, 1H), 4.30 (q, J = 6.8 Hz, 2H), 3.86 (s, 2H), 1.42 (t, J = 6.9 Hz, 3H).

[0583] Example 59: Synthesis of (3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)glycine (Compound 215)

[0584]

[0585] (3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)glycine was prepared using the procedure in Example 58. LCMS (ESI) = 407.2 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ7.95(d,J=8.6Hz,1H),7.56(d,J=8.6Hz,2H),7.36–7.27(m,2 H), 6.68 (d, J = 8.6Hz, 2H), 4.31 (q, J = 6.9Hz, 2H), 3.82 (s, 2H), 1.43 (t, J = 6.9Hz, 3H).

[0586] Example 60: Synthesis of 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (Compound 216)

[0587]

[0588] Step 1: To an 8 mL vial was added 5-(4-bromo-2-(cyclopentyloxy)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (200 mg, 0.403 mmol, 1.0 equiv) and tert-butyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate (202 mg, 0.604 mmol, 1.5 equiv), K2CO3 (167 mg, 1.21 mmol, 3.0 equiv), Pd(dppf)Cl2CHCl2 (32.9 mg, 0.040 mmol, 0.10 equiv), dioxane (3.0 mL) and H2O (0.30 mL). The mixture was stirred at 100°C for 2 h. The mixture was allowed to cool to room temperature, and the residue was purified by silica gel column chromatography to give tert-butyl 2-((3'-(cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (250 mg) as an off-white solid.

[0589] Step 2: To a 40 mL vial was added tert-butyl 2-((3'-(cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (250 mg, 0.401 mmol, 1.0 equiv) and HCl (g) in EA (5.0 mL saturated solution). The resulting mixture was stirred at 50 °C for 3 h. The resulting mixture was concentrated under reduced pressure to give 2-((3'-(cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (200 mg), which was used in the next step without purification.

[0590] Step 3: To an 8 mL vial was added 2-((3'-(cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (200 mg, 0.352 mmol, 1.0 equiv) and TFA (3.0 mL). The mixture was stirred at 60 °C for 2 h. The mixture was concentrated under reduced pressure, and the crude residue was purified by preparative HPLC to give 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (19.6 mg, 12%) as a white solid. LCMS (ESI) = 448.2 [M+H] + . 1 H NMR(300MHz, DMSO-d6)δ8.05(d,J=8.4Hz,1H),7.46–7.36(m,3H),7.33(d,J=7.8Hz,1H),7.24( s,1H),6.96(d,J=8.2Hz,1H),5.23(s,1H),4.68(s,2H),2.02–1.86(m,4H),1.81–1.51(m,4H).

[0591] Example 61: Synthesis of 2-((2'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (Compound 217)

[0592]

[0593] 2-((2'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid was prepared using the procedure in Example 60. LCMS (ESI) = 408.1 [M+H] + . 1 HNMR(300MHz,DMSO-d6)δ12.68(s,1H),7.88–7.79(m,2H),7.50(d,J=8.3Hz,1H),7.36(t,J=7.9Hz,1H),7 .23–7.09(m,2H),6.92(dd,J=8.7,2.6Hz,1H),4.72(s,2H),4.22(q,J=6.9Hz,2H),1.35(t,J=6.9Hz,3H).

[0594] Example 62: Synthesis of methyl 3'-ethoxy-5-(2-methoxy-2-oxoethoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate (Compound 218)

[0595]

[0596] Using the procedure in Example 55, methyl 3'-ethoxy-5-(2-methoxy-2-oxoethoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate was prepared from methyl 3-bromo-5-hydroxybenzoate and methyl bromoacetate. LCMS (ESI) = 480.2 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ7.99(d,J=8.5Hz,1H),7.90(s,1H),7.63(s,1H),7.51–7.41(m,3 H), 5.03 (s, 2H), 4.35 (t, J = 6.9Hz, 2H), 3.91 (s, 3H), 3.73 (s, 3H), 1.42 (t, J = 6.9Hz, 3H).

[0597] Example 63: Synthesis of 5-(carboxymethoxy)-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 219)

[0598]

[0599] Using the procedure in Example 9, 5-(carboxymethoxy)-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was synthesized from Compound 218. LCMS (ESI) = 452.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ8.01(d,J=8.1Hz,1H),7.78(s,1H),7.32(m,4H),4.47–4.24(m,4H),1.42(t,J=7.0Hz,3H).

[0600] Example 64: Synthesis of 3-(carboxymethoxy)-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 220)

[0601]

[0602] 3-(Carboxymethoxy)-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was synthesized from methyl 4-bromo-2-hydroxybenzoate and methyl bromoacetate using the procedures in Examples 55, 42, and 9. LCMS (ESI) = 452.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.25(s,1H),7.86(d,J=8.4Hz,1H),7.67(d,J=8.0Hz,1H),7.57 (s, 1H), 7.46 (d, J = 6.7Hz, 3H), 4.79 (s, 2H), 4.32 (q, J = 6.9Hz, 2H), 1.39 (t, J = 6.9Hz, 3H).

[0603] Example 65: Synthesis of (3'-ethoxy-4-((4-methoxybenzyl)oxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine tert-butyl ester (Compound 221)

[0604]

[0605]

[0606] Step 1: Into a 100-mL round-bottom flask was placed 4-bromo-2-nitrophenol (1.00 g, 4.59 mmol, 1.0 equiv), 4-chloroanisole (0.90 g, 6.31 mmol, 1.4 equiv), KCO (1.90 g, 13.7 mmol, 3.0 equiv), and acetone (20 mL). The resulting solution was stirred at 60° C. overnight. The resulting mixture was concentrated under vacuum, and the residue was purified by silica gel chromatography using ethyl acetate / petroleum ether (5 / 95) to give 4-bromo-1-((4-methoxybenzyl)oxy)-2-nitrobenzene (850 mg, 57%) as a yellow oil. LCMS (ESI) = 338.0 [M+H] + .

[0607] Step 2: Into a 100-mL round-bottom flask was placed 4-bromo-1-((4-methoxybenzyl)oxy)-2-nitrobenzene (850 mg, 2.51 mmol, 1.0 equiv), NHCl (668 mg, 12.5 mmol, 5.0 equiv), and Fe (420 mg, 7.52 mmol, 3.0 equiv) in EtOH (20 mL) and H2O (2 mL). The resulting solution was stirred at 70°C for 20 min. The solid was filtered, and the resulting mixture was concentrated under vacuum to give 5-bromo-2-((4-methoxybenzyl)oxy)aniline (700 mg, 90%) as a brown solid. LCMS (ESI) = 308.0 [M+H] + .

[0608] Tert-butyl (3'-ethoxy-4-((4-methoxybenzyl)oxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycate (Compound 221) was prepared using the procedure of Example 58. LCMS (ESI) = 599.3 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.14(s,1H),7.84(d,J=8.2Hz,1H),7.49–7.40(m,2H),7.34(d,J=7.5Hz,2H),7.09–6.95(m,3H),6.97(d,J=2.0Hz,1H),6.7 9(d,J=1.9Hz,1H),5.26(t,J=5.9Hz,1H),5.13(s,2H),4.29(q,J=6.9Hz,2 H), 3.98 (d, J = 5.9 Hz, 2H), 3.78 (s, 3H), 1.43 (s, 9H), 1.39 (t, J = 6.9 Hz, 3H).

[0609] Example 66: Synthesis of (3'-ethoxy-4-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (Compound 222)

[0610]

[0611] (3'-Ethoxy-4-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine was prepared from Compound 221 using the method in Step 4 of Example 55. LCMS (ESI) = 423.1 [M+H]+ . 1 H NMR(300MHz,DMSO-d6)δ8.01(d,J=8.2Hz,1H),7.29(d,J=7.7Hz,2H),6.84(s,1H ),6.81–6.70(m,2H),4.30(t,J=6.9Hz,2H),3.71(s,2H),1.44(t,J=6.9Hz,3H).

[0612] Example 67: Synthesis of (3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (Compound 223)

[0613]

[0614] (3'-Ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine was prepared from 3-bromo-5-nitrophenol and 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one using the procedures in Examples 65 and 60. LCMS (ESI) = 423.2 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ9.20(s,1H),7.93(d,J=8.4Hz,1H),7.25(dt,J=4.6,2.3Hz,2H),6.43– 6.32 (m, 2H), 6.04 (d, J = 2.1Hz, 1H), 4.28 (q, J = 6.8Hz, 2H), 3.78 (s, 2H), 1.42 (t, J = 6.9Hz, 3H).

[0615] Example 68: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)-2-methylpropanoic acid (Compound 224)

[0616]

[0617] In a 40 mL vial, a mixture of 3-bromoaniline (1.00 g, 5.81 mmol, 1.0 equiv), tert-butyl 2-bromo-2-methylpropanoate (1.50 g, 6.72 mmol), NaHCO (1.50 g, 17.9 mmol) in DMF (10 mL) was heated at 140° C. for 16 h. The mixture was allowed to cool to room temperature, and the residue was purified by silica gel column chromatography to give tert-butyl 2-((3-bromophenyl)amino)-2-methylpropanoate (120 mg, 7%) as a brown oil. 1 H NMR (300MHz, CDCl3) δ7.03 (t, J = 8.0 Hz, 1H), 6.95–6.82 (m, 2H), 6.63 (d, J = 8.0 Hz, 1H), 1.55 (s, 6H), 1.43 (s, 9H).

[0618] 2-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)-2-methylpropanoic acid was prepared from 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one. 1 H NMR (300MHz, DMSO-d6) δ11.94(s,1H),7.87(d,J=8.3Hz,1H),7.30–7.13(m,3H),6.93(d,J=7.6Hz,1H) ,6.86(t,J=2.0Hz,1H),6.59–6.50(m,1H),4.27(q,J=6.8Hz,2H),1.48(s,6H),1.41(t,J=6.9Hz,3H).

[0619] Example 69: Synthesis of (3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (Compound 225)

[0620]

[0621] (3'-(Cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine was prepared using the procedure in Example 58. LCMS (ESI) = 447.2 [M+H]+ . 1 HNMR(300MHz,DMSO-d6)δ12.03(s,1H),7.92(d,J=8.4Hz,1H),7.34(dq,J=3.5,1.6Hz,2H),7.23(t,J=7.8Hz,1H),7.02–6 .92(m,2H),6.67(dd,J=7.8,2.2Hz,1H),5.15(dt,J=5.7,3.0Hz,1H),3.92(s,2H),2.06–1.79(m,4H),1.77–1.53(m,4H).

[0622] Example 70: Synthesis of 3-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)propanoic acid (Compound 226)

[0623]

[0624]

[0625] 5-(3'-Amino-3-ethoxy-[1,1'-biphenyl]-4-yl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure in Example 1.

[0626] Step 1: To a stirred solution of 5-(3'-amino-3-ethoxy-[1,1'-biphenyl]-4-yl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (80.0 mg, 0.171 mmol, 1.0 equiv) and ethyl 3-oxopropanoate (0.50 mL) in AcOH (1.0 mL) was added NaBH(OAc) (362 mg, 1.71 mmol, 10 equiv) portionwise at room temperature. The resulting mixture was stirred for 10 min and then diluted with water (10 mL). The mixture was basified to pH 8 with NaHCO and extracted with EA (3 x 10 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give ethyl 3-((3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)propanoate (65 mg, 40%) as a pale yellow solid.

[0627] 3-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)propanoic acid was prepared using the procedures in Examples 6 and 9. LCMS (ESI) = 421.2 [M+H] + . 1 HNMR(300MHz,DMSO-d6)δ7.91(d,J=8.3Hz,1H),7.33(d,J=7.4Hz,2H),7.21(t,J=7.9Hz,1H),6.97–6.88(m,2H),6 .64(dd,J=7.3,1.9Hz,1H),4.29(q,J=6.9Hz,2H),3.33(t,J=6.7Hz,2H),2.58–2.50(m,2H),1.40(t,J=6.9Hz,3H).

[0628] Example 71: Synthesis of 4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-carboxylic acid (Compound 227)

[0629]

[0630]

[0631] 5-(4-Bromo-2-methoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure in Example 6.

[0632] Step 1: To a stirred solution of 5-(4-bromo-2-methoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (500 mg, 1.13 mmol, 1.0 equiv) in DMF (5.0 mL) was added portionwise NaH (90.4 mg, 2.26 mmol, 2.0 equiv, 60%) at room temperature under N2. The resulting mixture was stirred at room temperature for 30 min, then 4-methoxybenzyl chloride (212 mg, 1.36 mmol, 1.2 equiv) was added dropwise. The resulting mixture was stirred for 24 h, then quenched by the addition of water (20 mL). The mixture was extracted with EA (2 x 20 mL), and the combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 5-(4-bromo-2-methoxyphenyl)-3,6-bis(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (370 mg, 58%) as a yellow solid.

[0633] Step 2: To a stirred solution of 5-(4-bromo-2-methoxyphenyl)-3,6-bis(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (250 mg, 0.445 mmol, 1.0 equiv) in DMF (5.0 mL) was added LiCl (188 mg, 4.44 mmol, 10 equiv). The resulting mixture was stirred at 150° C. for 9 h and then allowed to cool to room temperature. The reaction was quenched by the addition of water (20 mL) and acidified to pH 3-4 with concentrated HCl. The mixture was extracted with EA (3×10 mL), and the combined organic layers were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 5-(4-bromo-2-hydroxyphenyl)-3,6-bis(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (230 mg, 55%) as a gray solid.

[0634] Step 3: To a solution of 5-(4-bromo-2-hydroxyphenyl)-3,6-bis(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (200 mg, 0.212 mmol, 1.0 equiv) and 4-(ethoxycarbonyl)phenylboronic acid (61.6 mg, 0.317 mmol, 1.5 equiv) in dioxane (3.0 mL) and H2O (0.30 mL) was added K2CO3 (87.7 mg, 0.635 mmol, 3.0 equiv) and Pd(dppf)Cl2CH2Cl2 (15.5 mg, 0.021 mmol, 0.10 equiv). After stirring at 100°C under N2 for 2 h, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give ethyl 4′-(3,6-bis(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3′-hydroxy-[1,1′-biphenyl]-4-carboxylate (150 mg, 34%) as a gray solid.

[0635] Step 4: To a stirred solution of ethyl 4'-(3,6-bis(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-hydroxy-[1,1'-biphenyl]-4-carboxylate (150 mg, 0.243 mmol, 1.0 equiv) and 1-(2-chloroethyl)pyrrolidine hydrochloride (12.4 mg, 0.073 mmol, 1.0 equiv) in DMF (2.0 mL) was added KCO (30.2 mg, 0.219 mmol, 3.0 equiv) at room temperature. The resulting mixture was stirred at 80 °C for 2 h. The resulting mixture was diluted with water (10 mL). The resulting mixture was extracted with EA (3 x 5 mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give ethyl 4'-(3,6-bis(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-carboxylate (65 mg, 37%) as a yellow solid.

[0636] 4'-(7-Oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedures in Examples 6 and 9. LCMS (ESI) = 447.2 [M+H] +. 1 H NMR(300MHz,DMSO-d6)δ8.06(d,J=8.3Hz,2H),8.02–7.91(m,3H),7.64(d,J=1.7Hz,1 H),7.53(dd,J=8.1,1.6Hz,1H),4.54(s,2H),3.01(s,2H),2.77(s,4H),1.76(s,4H).

[0637] Example 72: Synthesis of 3'-(2-(dimethylamino)ethoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 228)

[0638]

[0639] 3'-(2-(Dimethylamino)ethoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure in Example 71. LCMS (ESI) = 421.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ8.13–8.04(m,2H),8.00–7.91(m,2H),7.81(d,J=8.0Hz ,1H),7.62–7.50(m,2H),4.62(d,J=5.1Hz,2H),3.53–3.45(m,2H),2.82(s,6H).

[0640] Example 73: Synthesis of 3'-(3-(dimethylamino)propoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 229)

[0641]

[0642] 3'-(3-(Dimethylamino)propoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure in Example 71. LCMS (ESI) = 435.2 [M+H] + . 1H NMR(300MHz,DMSO-d6)δ11.06(s,1H),8.33(s,1H),8.02–7.93(m,3H),7.79(d,J=8.1Hz,2H),7.42 (d, J=8.9Hz, 2H), 4.30 (t, J=6.1Hz, 2H), 2.57 (t, J=7.0Hz, 2H), 2.26 (s, 6H), 1.99 (q, J=6.6Hz, 2H).

[0643] Example 74: Synthesis of (4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy)-[1,1'-biphenyl]-3-yl)glycine (Compound 230)

[0644]

[0645] (4'-(7-Oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy)-[1,1'-biphenyl]-3-yl)glycine was prepared using the procedure in Example 71, except that alkylation was performed with 1-(2-chloroethyl)pyrrolidine hydrochloride in Step 2, and the remaining steps were performed as in Example 58. LCMS (ESI) = 476.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.93(d,J=8.1Hz,1H),7.46(d,J=1.6Hz,1H),7.38(dd,J=8.0,1.5Hz,1H),7.21(t,J=7.8H z,1H),7.02–6.91(m,2H),6.64(d,J=8.3Hz,1H),4.51(s,2H),3.90(s,2H),3.03(s,2H),2.79(s,4H),1.77(s,4H).

[0646] Example 75: Synthesis of 6-(3-(cyclopentyloxy)-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinic acid (Compound 231)

[0647]

[0648] 6-(3-(cyclopentyloxy)-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinic acid was prepared from 6-bromonicotinic acid using the procedure in Example 42. LCMS (ESI) = 419.1 [M+H] + . 1 H NMR (300 MHz, DMSO-d6) δ 13.6 (broad s, 1H), 12.2 (broad s, 1H), 9.20 (s, 1H), 8.39 (dd, J = 8.1, 2.1 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 7.80–8.00 (m, 3H), 5.10-5.20 (m, 1H), 1.75-2.05 (m, 4H), 1.55-1.75 (m, 4H).

[0649] Example 76: Synthesis of 5-(3-ethoxy-3'-(methylamino)-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 232)

[0650]

[0651] 5-(3-Ethoxy-3'-(methylamino)-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared from N-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline using the procedure in Example 6. LCMS (ESI) = 363.2 [M+H] + .

[0652] Example 77: Synthesis of 5-(3-(cyclopentyloxy)-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinic acid (Compound 233)

[0653]

[0654] 5-(3-(cyclopentyloxy)-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinic acid was prepared from methyl 5-bromopicolinate using the procedures in Examples 42 and 9. LCMS (ESI) = 419.2 [M+H] + . 1H NMR (300MHz, DMSO-d6) δ11.7 (width s, 1H), 9.11 (s, 1H), 8.38 (d, J = 8.4Hz, 1H), 8.10-8.18 (m, 1H), 8.14 (s, 1H),8.03(d,J=7.8,1H),7.50–7.60(m,2H),5.18-5.28(m,1H),1.80–2.00(m,4H),1.55-1.75(m,4H).

[0655] Example 78: Synthesis of 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)propanoic acid (Compound 234)

[0656]

[0657] 3-(3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)propanoic acid was prepared from 3-(3-bromophenyl)propanoic acid using the procedure in Example 42. LCMS (ESI) = 406.1 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ12.17(s,2H),7.87(d,J=8.1Hz,1H),7.69–7.56(m,2H),7.41(d,J=7.5Hz,3H),7 .35–7.26(m,1H),4.31(q,J=6.9Hz,2H),2.93(t,J=7.7Hz,2H),2.68–2.52(m,2H),1.40(t,J=6.9Hz,3H).

[0658] Example 79: Synthesis of (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)acrylic acid (Compound 235)

[0659]

[0660] (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)acrylic acid was prepared from (E)-3-(3-bromophenyl)acrylic acid using the procedure in Example 42. LCMS (ESI) = 404.1 [M+H] + .1 H NMR(300MHz,DMSO-d6)δ8.12(s,1H),7.92(d,J=8.1Hz,1H),7.88–7.66(m,3H),7.56(t,J=7.7Hz, 1H), 7.49 (d, J = 8.1Hz, 2H), 6.72 (d, J = 16.0Hz, 1H), 4.34 (q, J = 6.8Hz, 2H), 1.41 (t, J = 6.9Hz, 3H).

[0661] Example 80: Synthesis of (Z)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylpropenoic acid (Compound 236) and (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylpropenoic acid (Compound 237)

[0662]

[0663] Step 1: Into a 50-mL round-bottom flask was placed 3-bromobenzaldehyde (1.84 g, 9.94 mmol, 1.00 equiv) and methyl acrylate (2.57 g mg, 29.8 mmol, 3.00 equiv) in dioxane (0.50 mL) and H O (0.50 mL), and DABCO (1.12 g, 9.94 mmol, 1.00 equiv) was added. The resulting solution was stirred at room temperature for 14 hours. The residue was applied to a silica gel column with ethyl acetate / petroleum ether (1:10). This yielded 2.5 g (93%) of methyl 2-((3-bromophenyl)(hydroxy)methyl)acrylate as a colorless oil. 1 H NMR (300MHz, DMSO-d6) δ7.78–7.35(m,2H),6.24(t,J=1.5Hz,2H),6.20(s,1H),6.02(s,1H),5.88(brs,1H),5.43(d,J=1.5Hz,1H),3.62(s,3H).

[0664] Step 2: To methyl 2-((3-bromophenyl)(hydroxy)methyl)acrylate (250 mg, 0.922 mmol, 1.00 equiv) was added THF (2.0 mL) and I (515 mg, 2.03 mmol, 2.20 equiv). The resulting brown solution was cooled to 0°C. NaBH (69.8 mg, 1.84 mmol, 2.00 equiv) was added in small portions, and the white suspension was stirred for 17 h. The reaction was quenched by the addition of H2O (5 ml) at 0°C. The resulting mixture was extracted with DCM (3 x 5 mL). The combined organic layers were washed with NaCl (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl (E)-3-(3-bromophenyl)-2-methacrylate (40 mg, 17%) as a yellow oil. 1 H NMR (300MHz, CDCl3) δ7.63 (s, 1H), 7.55 (s, 1H), 7.48 (dt, J = 7.3, 1.9Hz, 1H), 7.41–7.23 (m, 2H), 3.85 (s, 3H), 2.13 (d, J = 1.5Hz, 3H).

[0665] Step 3: To a solution of 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (94.7 mg, 0.188 mmol, 1.20 equiv) and (2E)-methyl 3-(3-bromophenyl)-2-methylprop-2-enoate (40.0 mg, 0.157 mmol, 1.00 equiv) in dioxane (1.0 mL) and H2O (0.1 mL) were added K2CO3 (65.0 mg, 0.470 mmol, 3.00 equiv) and Pd(dppf)Cl2 (11.5 mg, 0.016 mmol, 0.10 equiv). After stirring at 100° C. for 2 h under a nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give (E)-methyl 3-(3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methacrylate (100 mg) as a white solid. LCMS (ESI) = 552.2 [M+H] + .

[0666] Step 4: Into an 8-mL vial was placed methyl (E)-3-(3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methacrylate (40.0 mg, 0.073 mmol, 1.00 equiv) in trifluoroacetic acid (1.0 mL). The resulting solution was stirred at 80°C for 2 hr and then concentrated under reduced pressure. This resulted in 40 mg of (E)-methyl 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methacrylate as a yellow solid, which was carried on without further purification. LCMS (ESI) = 432.2 [M+H] + .

[0667] Step 5: Into an 8-mL vial was placed (E)-methyl 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methacrylate (40.0 mg) in DMSO (1.0 mL), followed by the addition of 2N NaOH (1.0 mL). The resulting solution was stirred at room temperature for 2 hours. The pH was adjusted to pH 6 by the addition of AcOH. The crude product was purified by preparative HPLC to give 1.6 mg (4.0%) of (Z)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid (peak 1) as a white solid, and 8.3 mg (21%) of (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid (peak 2) as a white solid.

[0668] Data of (Z)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid: LCMS (ESI) = 418.0 [M+H] + . 1H NMR(300MHz,DMSO-d6)δ11.02(brs,1H)8.01(d,J=8.4Hz,1H),7.81(s,1H),7.59(d,J=7.2H z,1H),7.48–7.36(m,4H),4.35–4.28(m,2H),2.03(d,J=1.2Hz,3H),1.44(d,J=6.9Hz,3H).

[0669] Data of (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid: LCMS (ESI) = 418.0 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ8.00(d,J=8.1Hz,1H),7.84(s,1H),7.77(d,J=7.8Hz,1H),7.72(s,1H),7.60–7 .51(m,2H),7.44(d,J=6.9Hz,2H),4.33(q,J=6.9Hz,2H),2.10(d,J=1.2Hz,3H),1.43(t,J=6.6Hz,3H).

[0670] Example 81: Synthesis of 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylpropanoic acid (Compound 238)

[0671]

[0672] To a solution of (E)-methyl 3-(3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methacrylate (60.0 mg, 0.109 mmol, 1.00 equiv) in MeOH (1.0 mL) was added Pd / C (10.0 mg). Hydrogen gas was introduced via a hydrogen balloon, and the mixture was stirred at room temperature for 2 h. The mixture was filtered through a pad of Celite and concentrated under reduced pressure. This resulted in methyl 3-(3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylpropanoate (40 mg, 66%) as a white solid. LCMS (ESI) = 554.3 [M+H] + .

[0673] 3-(3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylpropanoic acid was prepared using the procedures in Examples 6 and 9. LCMS (ESI) = 420.1 [M+H] + . 1 HNMR(300MHz,DMSO-d6)δ8.00(d,J=8.4Hz,1H),7.61(d,J=1.8Hz,2H),7.44–7.37(m,3H),7.24(d,J=7.5Hz,1 H),4.33(q,J=6.9Hz,2H),3.05–2.96(m,1H),2.77–2.70(m,2H),1.43(t,J=6.9Hz,3H),1.10(d,J=6.3Hz,3H).

[0674] Example 82: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid (Compound 239)

[0675] Step 1: To a stirred solution of ethyl butyrate (1.00 g, 8.61 mmol, 1.00 equiv) in THF (20 mL) at -78°C under N2 was added LDA (2 M) (4.74 mL) dropwise. The resulting mixture was stirred at -30°C under N2 for 1.5 hr. To the above mixture was added 1-bromo-3-(bromomethyl)benzene (2.37 g, 9.47 mmol, 1.1 equiv) dropwise at -30°C over 15 min. The resulting mixture was stirred at -30°C for an additional 3 hr. The reaction was quenched by the addition of 1 M HCl (20 mL) at 5°C. The resulting mixture was extracted with Et2O (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 ml), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give ethyl 2-(3-bromobenzyl)butanoate (800 mg, 26.4%) as a white solid.

[0676] Step 2: To a 20 ml vial was added ethyl 2-(3-bromobenzyl)butanoate (800 mg, 2.80 mmol, 1.00 equiv) and bis(pinacolato)diboron (1.42 g, 5.61 mmol, 2.0 equiv), KOAc (551 mg, 5.61 mmol, 2.0 equiv), dioxane (10.0 mL), and Pd(dppf)Cl2 (205 mg, 0.281 mmol, 0.1 equiv) at room temperature. The resulting mixture was stirred at 100 ° C for 2 hours, and then the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give ethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)butanoate (700 mg, 62%) as a white solid.

[0677] 2-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid was prepared using the procedures in Examples 1 and 9. LCMS (ESI) = 434.2 [M+H] + . 1HNMR (300MHz, DMSO-d6) δ8.23(d,J=8.4Hz,1H),7.55(d,J=9.0Hz,2H),7.46–7.35(m,1H),7.40(s,2H),7.28(d,J=7.6Hz,1H),4.41(q, J=7.0Hz,2H),3.02(dd,J=13.6,8.9Hz,1H),2.86(dd,J=13.6,6.0Hz,1H),2.71–2.55(m,1H),1.78–1.53(m,4H),1.00(t,J=7.4Hz,3H).

[0678] Example 83: Separation of the Enantiomers of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic Acid (Compound 240 and Compound 241)

[0679]

[0680] 2-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid (racemic) (58 mg) was separated into individual enantiomers by chiral preparative HPLC using a CHIRALPAK IC-3 column, 20*250 mm, 5 um; mobile phase, 20 mL / min. Phase A: n-hexane / DCM = 5 / 1, phase B: ethanol (0.1% TFA). This resulted in (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid (18 mg, 36%, ee% = 99.5%) as a white solid and (R)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid (17.8 mg, 36%, ee% = 99.2%) as a white solid.

[0681] Data of compound 240 (peak 1): LCMS (ESI) = 434.2 [M+H] + HPLC (CHIRALPAK IC-3, 4.6x50mm, 3μm, 1.0mL / min); A: n-hexane:DCM5 / 1; B: EtOH containing 0.1% TFA; 25% B): t R= 2.27 min. *The absolute stereochemistry of the isolated individual enantiomers was not determined.

[0682] Data of compound 241 (peak 2): LCMS (ESI) = 434.2 [M+H] + HPLC (CHIRALPAK IC-3, 4.6x50 mm, 3 μm, 1.0 mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH containing 0.1% TFA; 25% B): t R = 2.78 min. *The absolute stereochemistry of the isolated individual enantiomers was not determined.

[0683] Example 84: Synthesis of ethyl 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2,2-dimethylpropanoate (Compound 242)

[0684]

[0685] Ethyl 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2,2-dimethylpropanoate was prepared from ethyl isobutyrate using the procedure in Example 82. LCMS (ESI) = 462.3 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ11.68(s,1H),7.93(d,J=8.3Hz,1H),7.63(d,J=7.9Hz,1H),7.51–7.31(m,4H),7.17(d,J=7.6Hz, 1H), 4.30 (q, J = 6.9Hz, 2H), 4.07 (q, J = 7.1Hz, 2H), 2.92 (s, 2H), 1.41 (t, J = 6.9Hz, 3H), 1.18 (t, J = 7.1Hz, 3H), 1.16 (s, 6H).

[0686] Example 85: Synthesis of 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2,2-dimethylpropanoic acid (Compound 243)

[0687]

[0688] 3-(3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2,2-dimethylpropanoic acid was prepared using the ester hydrolysis procedure in Example 9. LCMS (ESI) = 434.2 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ7.98(d,J=8.4Hz,1H),7.62(d,J=7.7Hz,1H),7.53(s,1H),7.46–7.31(m,3 H), 7.21 (d, J = 7.5Hz, 1H), 4.31 (q, J = 6.8Hz, 2H), 2.90 (s, 2H), 1.42 (t, J = 6.9Hz, 3H), 1.13 (s, 6H).

[0689] Example 86: Synthesis of 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclopropane-1-carboxylic acid (Compound 244)

[0690]

[0691] 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclopropane-1-carboxylic acid was prepared from tert-butyl cyclopropanecarboxylate using the procedures in Examples 82 and 58. LCMS (ESI) = 433.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.96(d,J=8.5Hz,1H),7.65(t,J=1.7Hz,1H),7.59(dt,J=7.7,1.6Hz,1H),7.46–7.29( m, 4H), 4.31 (q, J = 6.9Hz, 2H), 2.98 (s, 2H), 1.42 (t, J = 6.9Hz, 3H), 1.15 (q, J = 3.7Hz, 2H), 0.89 (q, J = 3.9Hz, 2H).

[0692] Example 87: Synthesis of ethyl 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclobutane-1-carboxylate (Compound 245)

[0693]

[0694] Ethyl 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclobutane-1-carboxylate was prepared using the procedure in Example 82. LCMS (ESI) = 474.3 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.07 (s, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.63 (d, J = 7. 8Hz,1H),7.50(s,1H),7.47–7.32(m,3H),7.19(d,J=7.4Hz,1H),4.30(q,J= 6.9Hz,2H),4.08(q,J=7.1Hz,2H),3.17(s,2H),2.40–2.28(m,2H),2.16–2. 02(m,2H),1.99–1.72(m,2H),1.41(t,J=6.9Hz,3H),1.15(t,J=7.1Hz,3H).

[0695] Example 88: Synthesis of 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclobutane-1-carboxylic acid (Compound 246)

[0696]

[0697] 1-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclobutane-1-carboxylic acid was prepared using the ester hydrolysis procedure in Example 9. LCMS (ESI) = 446.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.93(d,J=8.2Hz,1H),7.61(d,J=7.9Hz,1H),7.54(s,1H),7.46–7.32(m,3H),7.24(d,J=7.7Hz, 1H),4.31(q,J=6.9Hz,2H),3.15(s,2H),2.39–2.22(m,2H),2.12–1.97(m,2H),1.96–1.71(m,2H),1.42(t,J=6.9Hz,3H.

[0698] Example 89: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 247)

[0699]

[0700] To a solution of methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)butanoate (prepared from methyl 2-bromobutanoate using the method in Example 56) (50.0 mg, 0.156 mmol, 1.00 equiv) and 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (52.5 mg, 0.156 mmol, 1.00 equiv) in dioxane (0.50 mL) and H2O (0.10 mL) were added K2CO3 (64.8 mg, 0.468 mmol, 3.00 equiv) and Pd(dppf)Cl2 (11.4 mg, 0.011 mmol, 0.10 equiv). After stirring at 100 ° C. under a nitrogen atmosphere for 16 hours, the resulting mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (15.7 mg, 23%) as an off-white solid. LCMS (ESI) = 436.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.05(s,1H),7.88(d,J=8.4Hz,1H),7.38(dt,J=11.0,6.9Hz,4H),7.26(s,1H),6.95(d,J=8.1 Hz,1H),4.83(t,J=6.0Hz,1H),4.31(q,J=6.9Hz,2H),2.00–1.85(m,2H),1.40(t,J=6.9Hz,3H),1.05(t,J=7.4Hz,3H).

[0701] Example 90: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)pentanoic acid (Compound 248)

[0702]

[0703] 2-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)pentanoic acid was prepared using the procedure in Example 89. LCMS (ESI) = 450.2 [M+H] + . 1 HNMR(300MHz,DMSO-d6)δ12.20(s,1H),7.86(d,J=8.2Hz,1H),7.48–7.31(m,4H),7.26(s,1H),6.94(d,J=8.1Hz,1H),4.87(t,J = 6.3Hz, 1H), 4.31 (q, J = 6.9Hz, 2H), 1.89 ( q, J = 7.0Hz, 2H), 1.52 ( q, J = 7.7Hz, 2H), 1.40 ( t, J = 6.9Hz, 3H), 0.96 ( t, J = 7.3Hz, 3H).

[0704] Example 91: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-2-phenylacetic acid (Compound 249)

[0705]

[0706] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-2-phenylacetic acid was prepared from ethyl 2-bromo-2-phenylacetate using the procedure in Example 89. LCMS (ESI) = 484.2 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ7.93(d,J=8.0Hz,1H),7.66–7.57(m,2H),7.47–7.29(m,8 H),7.05–6.96(m,1H),5.82(s,1H),4.31(q,J=6.9Hz,2H),1.41(t,J=6.9Hz,3H).

[0707] Example 92: Synthesis of 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 250)

[0708]

[0709] 2-((3'-(Cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedure in Example 89. 462.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ8.02(d,J=8.4Hz,1H),7.46–7.33(m,3H),7.33(d,J=7.7Hz,1H),7.23(t,J=2.1Hz,1H),6.93(ddd,J= 8.1, 2.6, 1.1Hz, 1H), 5.25–5.18 (m, 1H), 4.94 (d, J = 7.5Hz, 1H), 2.02–1.80 (m, 4H), 1.79–1.59 (m, 4H), 1.54 (d, J = 6.7Hz, 3H).

[0710] Example 93: Synthesis of (R)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 251)

[0711] Step 1: To a stirred solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.00 g, 4.54 mmol, 1.00 equiv), (S)-methyl 2-hydroxypropanoate (0.52 g, 5.00 mmol, 1.10 equiv) and PPh (1.55 g, 5.90 mmol, 1.30 equiv) in THF (10 mL) was added DIAD (1.19 g, 5.91 mmol, 1.30 equiv) dropwise at 0° C. under N atmosphere. The resulting mixture was stirred at room temperature for 16 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give (R)-methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propanoate (500 mg, 36%) as an off-white oil. LCMS (ESI) = 307.2 [M+H] + .

[0712] Step 2: To a solution of (R)-methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propanoate (90.0 mg, 0.294 mmol, 1.00 equiv) and 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (98.8 mg, 0.294 mmol, 1.0 equiv) in dioxane (1.0 mL) and H2O (0.3 mL) was added K2CO3 (122 mg, 0.882 mmol, 3.00 equiv) and Pd(dppf)Cl2 (21.5 mg, 0.029 mmol, 0.1 equiv). After stirring at 100°C under nitrogen atmosphere for 16 h, the resulting mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC to give (R)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (15.7 mg, 13%) as an off-white solid. LCMS (ESI) = 422.1 [M+H] + . 1 H NMR (300 MHz, DMSO-d6) δ 7.97 (d, J = 8.5 Hz, 1H), 7.40–7.25 (m, 4H), 7.21 (d, J = 2.2 Hz, 1H), 6.89 (dd, J = 8.7, 1.9 Hz, 1H), 4.77 (d, J = 6.9 Hz, 1H), 4.31 (q, J = 7.0 Hz, 2H), 1.49 (d, J = 6.7 Hz, 3H), 1.42 (t, J = 6.9 Hz, 3H). Analytical chiral HPLC: CHIRALPAK AD-3 column [100*3 mm, 3 μm, 1.5 mL / min, 50% hexane:DCM (5:1)–100% EtOH (containing 0.1% TFA)]: t R 2.01 min (peak 1).

[0713] Example 94: Synthesis of (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 252)

[0714]

[0715] (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from (R)-methyl 2-hydroxypropanoate using the procedure in Example 89. LCMS (ESI) = 422.1 [M+H] + Analytical chiral HPLC: CHIRALPAK AD-3 column [100*3 mm, 3 μm, 1.5 mL / min, 50% hexane:DCM (5:1)–100% EtOH (containing 0.1% TFA)] R 3.48 min (peak 2).

[0716] Example 95: Synthesis of (R)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 253) and (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 254).

[0717]

[0718] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid was purified into individual enantiomers using a CHIRALPAK IC-3 column, 20*250 mm, 5 μM. A: n-hexane / DCM, 5 / 1. B: EtOH containing 0.1% TFA, 20% B.

[0719] Data for (R)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (peak 1): LCMS (ESI) = 436.1 [M+H] + . 1H NMR (300 MHz, DMSO-d6) δ 12.21 (s, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.48–7.31 (m, 4H), 7.26 (t, J = 2.1 Hz, 1H), 6.99–6.90 (m, 1H), 4.84 (dd, J = 6.8, 5.2 Hz, 1H), 4.31 (q, J = 7.0 Hz, 2H), 2.02–1.85 (m, 2H), 1.39 (t, J = 6.9 Hz, 3H), 1.04 (t, J = 7.4 Hz, 3H). Analytical chiral SFC: CHIRALPAKAD-3; 100 × 3.0 mm, 3 μm, EtOH (0.2% MSA), 1.5 mL / min; Pump B: 50.0%, t R =1.51min.

[0720] Data for (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (peak 2): LCMS (ESI) = 436.1 [M+H] + Chiral SFC: CHIRALPAK AD-3; 100*3.0 mm, 3 μm, EtOH (0.2% MSA), 1.5 mL / min; Pump B: 50.0%, t R =3.94min.

[0721] Example 96A: Synthesis of (R)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 255)

[0722]

[0723] (R)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from (R)-2-(3-bromo-5-hydroxyphenoxy)propanoic acid methyl ester using the procedures in Examples 93, 42, and 9. LCMS (ESI) = 438.1 [M+H] + . 1H NMR (300 MHz, DMSO-d6) δ 9.65 (s, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.31–7.22 (m, 2H), 6.68 (d, J = 7.7 Hz, 2H), 6.32 (s, 1H), 4.82–4.70 (m, 1H), 4.29 (q, J = 6.8 Hz, 2H), 1.49 (d, J = 6.7 Hz, 3H), 1.41 (t, J = 6.9 Hz, 3H). Analytical chiral HPLC: CHIRALPAK AD-3 (100 × 3 mm, 3 μM, 1.5 mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH containing 0.1% TFA; 30% B): t R =1.96 min (peak 1).

[0724] Example 96B: Synthesis of (S)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 256)

[0725]

[0726] (S)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from (S)-2-(3-bromo-5-hydroxyphenoxy)propanoic acid methyl ester using the procedure in Example 96A. LCMS (ESI) = 438.1 [M+H] + . 1 H NMR (300 MHz, DMSO-d6) δ 9.65 (s, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.31–7.22 (m, 2H), 6.68 (d, J = 7.7 Hz, 2H), 6.32 (s, 1H), 4.82–4.70 (m, 1H), 4.29 (q, J = 6.8 Hz, 2H), 1.49 (d, J = 6.7 Hz, 3H), 1.41 (t, J = 6.9 Hz, 3H). Analytical chiral HPLC: CHIRALPAK AD-3 (100 × 3 mm, 3 μM, 1.5 mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH containing 0.1% TFA; 30% B): t R =2.68 min (peak 2).

[0727] Example 97: Synthesis of 2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 257)

[0728]

[0729] 2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid was prepared from methyl 2-bromobutanoate and 5-bromobenzene-1,3-diol using the procedures in Examples 42 and 9. LCMS (ESI) = 452.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.93(d,J=8.4Hz,1H),7.31–7.22(m,2H),6.68(dt,J=9.3,1.8Hz,2H),6.35(t,J=2.1Hz,1H),4.38(dd,J= 7.1, 5.1Hz, 1H), 4.28 (q, J = 6.9Hz, 2H), 3.17 (s, 2H), 1.82 (dp, J = 14.0, 7.1Hz, 2H), 1.40 (t, J = 6.9Hz, 3H), 1.03 (d, J = 24.0Hz, 8H).

[0730] Example 98: Synthesis of (R)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 258)

[0731]

[0732] (R)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid was prepared from (S)-methyl 2-hydroxybutanoate and 5-bromobenzene-1,3-diol using the procedures in Examples 93, 42, and 9. LCMS (ESI) = 452.1 [M+H] + . 1H NMR (300 MHz, DMSO-d6) δ 9.72 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.33–7.24 (m, 2H), 6.70 (dt, J = 9.6, 1.7 Hz, 2H), 6.34 (t, J = 2.1 Hz, 1H), 4.61 (t, J = 6.2 Hz, 1H), 4.29 (q, J = 6.9 Hz, 2H), 1.97–1.77 (m, 2H), 1.40 (t, J = 6.9 Hz, 3H), 1.02 (t, J = 7.4 Hz, 3H). Analytical chiral HPLC: CHIRALPAK ID-3 (50*4.6 mm, 3 μm, 1 mL / min; A: hexane / DCM, 5 / 1; B: EtOH containing 0.1% TFA; 50% B). R =1.57 min (peak 1).

[0733] Example 99: Synthesis of (S)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 259)

[0734]

[0735] Using the procedure in Example 95, (S)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid was separated by preparative chiral HPLC using a CHIRALPAK IC-3 column. LCMS (ESI) = 452.1 [M+H] + Analytical chiral HPLC: CHIRALPAKID-3 (50*4.6 mm, 3 μm, 1 mL / min); A: hexane / DCM, 5 / 1; B: EtOH containing 0.1% TFA; 50% B. t R =2.43 min (peak 2).

[0736] Example 100: Synthesis of (R)-2-((3'-ethoxy-4,5-difluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 260)

[0737]

[0738] Step 1: To a 50 ml round-bottom flask was added 5-bromo-2,3-difluorophenol (500 mg, 2.32 mmol, 1.00 equiv), (S)-methyl 2-hydroxypropanoate (479 mg, 2.87 mmol, 1.2 equiv), PPh3 (816 mg, 3.11 mmol, 1.3 equiv) and THF (10 mL). To the above mixture was added DIAD (629 mg, 3.11 mmol, 1.3 equiv) dropwise at 0°C over 15 min. The resulting mixture was stirred at room temperature for an additional 12 hr, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl (R)-2-(5-bromo-2,3-difluorophenoxy)propanoate (450 mg, 58%) as a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ7.37 (ddd, J=9.7, 6.3, 2.3Hz, 1H), 7.23 (dt, J=6.7, 2.2Hz, 1H), 5.33–5.11 (m, 1H), 3.70 (s, 3H), 1.54 (d, J=6.8Hz, 3H).

[0739] Step 2: To a 40 ml vial was added (R)-methyl 2-(5-bromo-2,3-difluorophenoxy)propanoate (300 mg, 1.02 mmol, 1.00 equiv), bis(pinacolato)diboron (310 mg, 1.22 mmol, 1.2 equiv), KOAc (299 mg, 3.05 mmol, 3.0 equiv), dioxane (6.0 mL), and Pd(dppf)Cl (74.4 mg, 0.102 mmol, 0.10 equiv), and the resulting mixture was stirred at 100° C. for 2 hr. The mixture was purified by silica gel column chromatography to give methyl (R)-2-(2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propanoate (350 mg, 92%) as a yellow oil.

[0740] (R)-2-((3'-Ethoxy-4,5-difluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedure in Example 89. LCMS (ESI) = 458.0 [M+H] + . 1H NMR (300 MHz, DMSO-d6) δ 7.89 (d, J = 7.9 Hz, 1H), 7.42 (ddd, J = 11.6, 6.7, 2.0 Hz, 1H), 7.39–7.29 (m, 2H), 7.20 (d, J = 6.9 Hz, 1H), 5.02 (d, J = 7.0 Hz, 1H), 4.28 (tt, J = 7.0, 3.9 Hz, 2H), 1.52 (d, J = 6.7 Hz, 3H), 1.39 (t, J = 6.9 Hz, 3H). Analytical chiral HPLC: CHIRALPAK IC-3 (50*4.6 mm, 3 μm, 1 mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH containing 0.1% TFA), 15% B. t R =1.72 min (peak 1).

[0741] Example 101: Synthesis of (S)-2-((3'-ethoxy-4,5-difluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 261)

[0742]

[0743] (S)-2-((3'-ethoxy-4,5-difluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from (R)-methyl 2-hydroxypropanoate using the procedure in Example 100. LCMS (ESI) = 458.0 [M+H] + . 1 H NMR (300 MHz, DMSO-d6) δ 7.88 (d, J = 8.0 Hz, 1H), 7.42 (ddd, J = 11.5, 6.6, 1.9 Hz, 1H), 7.39–7.29 (m, 2H), 7.20 (d, J = 6.9 Hz, 1H), 5.01 (q, J = 6.7 Hz, 1H), 4.28 (qd, J = 7.0, 1.8 Hz, 2H), 1.52 (d, J = 6.7 Hz, 3H), 1.38 (t, J = 6.9 Hz, 3H). Analytical chiral HPLC: CHIRALPAK IC-3 (50*4.6 mm, 3 μm, 1 mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH containing 0.1% TFA; 15% B). R =3.79 min (peak 2).

[0744] Example 102: Synthesis of (R)-2-((3'-ethoxy-5-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 262)

[0745]

[0746] (R)-2-((3'-Ethoxy-5-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedure in Example 100. LCMS (ESI) = 440.0 [M+H] + . 1 H NMR (300 MHz, DMSO-d6) δ 7.93 (d, J = 8.5 Hz, 1H), 7.43–7.35 (m, 2H), 7.21 (dt, J = 9.9, 1.9 Hz, 1H), 7.12 (t, J = 1.9 Hz, 1H), 6.77 (dt, J = 11.0, 2.2 Hz, 1H), 4.89 (d, J = 7.0 Hz, 1H), 4.32 (q, J = 6.9 Hz, 2H), 1.51 (d, J = 6.7 Hz, 3H), 1.40 (t, J = 6.9 Hz, 3H). Analytical chiral HPLC: CHIRALPAK IA-3 (50*4.6 mm, 3 μm, 1 mL / min); A: n-hexane / DCM, 5 / 1; B: EtOH containing 0.1% TFA, 50% B). t R =0.923 min (peak 1).

[0747] Example 103: Synthesis of (S)-2-((3'-ethoxy-5-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 263)

[0748]

[0749] (S)-2-((3'-ethoxy-5-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedure in Example 100. LCMS (ESI) = 440.2 [M+H] + . 1H NMR (300 MHz, DMSO-d6) δ7.93 (d, J = 8.5 Hz, 1H), 7.43–7.35 (m, 2H), 7.21 (dt, J = 9.9, 1.9 Hz, 1H), 7.12 (t, J = 1.9 Hz, 1H), 6.77 (dt, J = 11.0, 2.2 Hz, 1H), 4.89 (d, J = 7.0 Hz, 1H), 4.32 (q, J = 6.9 Hz, 2H), 1.51 (d, J = 6.7 Hz, 3H), 1.40 (t, J = 6.9 Hz, 3H). Analytical chiral HPLC: CHIRALPAK IA-3 (50*4.6 mm, 3 μm, 1 mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH containing 0.1% TFA, 50% B). R =1.23 min (peak 2).

[0750] Example 104: Synthesis of (R)-2-((3'-ethoxy-4-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 264)

[0751]

[0752] (R)-2-((3'-ethoxy-4-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedure in Example 100. LCMS (ESI) = 440.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.94 (d, J=8.0Hz, 1H), 7.29 (ddd, J=10.1, 5.1, 3.1Hz, 5H), 4. 80(q,J=6.7Hz,1H),4.35–4.20(m,2H),1.49(d,J=6.7Hz,3H),1.40(t,J=6.9Hz,3H).

[0753] Example 105: Synthesis of (S)-2-((3'-ethoxy-4-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 265)

[0754]

[0755] (S)-2-((3'-ethoxy-4-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedure in Example 100. LCMS (ESI) = 440.2 [M+H] + . 1 H NMR(300MHz, DMSO-d6)δ7.91(d,J=7.9Hz,1H),7.38–7.25(m,5H),4.94(q,J=6.6H z, 1H), 4.27 (qd, J = 6.8, 2.2Hz, 2H), 1.51 (d, J = 6.6Hz, 3H), 1.39 (t, J = 6.9Hz, 2H).

[0756] Example 106: Synthesis of (R)-2-((3'-ethoxy-5-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 266)

[0757]

[0758] (R)-2-((3'-ethoxy-5-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from (S)-methyl 2-hydroxypropanoate using the procedure in Example 100. LCMS (ESI) = 436.1 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ7.96(d,J=8.2Hz,1H),7.38–7.30(m,2H),7.15(s,1H),7.02(s,1H),6.73(s ,1H),4.83(s,1H),4.31(q,J=6.8Hz,2H),2.35(s,3H),1.50(d,J=6.6Hz,3H),1.42(t,J=6.9Hz,3H).

[0759] Example 107: Synthesis of (S)-2-((3'-ethoxy-5-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 267)

[0760]

[0761] (S)-2-((3'-ethoxy-5-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from (R)-methyl 2-hydroxypropanoate using the procedure in Example 100. LCMS (ESI) = 436.1 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ7.96(d,J=8.2Hz,1H),7.38–7.30(m,2H),7.15(s,1H),7.02(s,1H),6.73(s ,1H),4.83(s,1H),4.31(q,J=6.8Hz,2H),2.35(s,3H),1.50(d,J=6.6Hz,3H),1.42(t,J=6.9Hz,3H).

[0762] Example 108: Synthesis of ethyl 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-3-methylbutanoate (Compound 268)

[0763]

[0764] Ethyl 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-3-methylbutanoate was prepared using the procedure in Example 56. LCMS (ESI) = 478.3 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ12.22(s,1H),7.86(d,J=8.5Hz,1H),7.48–7.33(m,4 H),7.29–7.22(m,1H),6.94(ddd,J=7.9,2.6,1.4Hz,1H),4.77(d,J=5.2Hz,1 H),4.31(q,J=6.9Hz,2H),4.17(q,J=7.0Hz,2H),2.24(dt,J=11.9,6.7Hz,1H ), 1.39 (t, J = 6.9 Hz, 3H), 1.18 ( t, J = 7.1 Hz, 3H), 1.05 ( dd, J = 6.8, 2.9 Hz, 6H).

[0765] Example 109: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-3-methylbutanoic acid (Compound 269)

[0766]

[0767] 2-((3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-3-methylbutanoic acid was prepared using the procedure in Example 56. LCMS (ESI) = 450.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.98(d,J=7.9Hz,1H),7.34(q,J=4.8Hz,3H),7.26(d,J=7.7Hz,1H),7.19(s,1H),6.92–6 .83(m,1H),4.32(t,J=7.0Hz,1H),4.26(s,2H),2.17(s,1H),1.41(t,J=6.9Hz,3H),1.01(dd,J=6.8,2.6Hz,6H).

[0768] Example 110: Synthesis of ethyl 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (Compound 270)

[0769]

[0770] Ethyl 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate was prepared using the procedure in Example 56. LCMS (ESI) = 476.2 [M+H] + . 1H NMR(300MHz,DMSO-d6)δ12.06(s,1H),7.93(d,J=8.4Hz,1H),7.49–7.33(m,4H),7 .29(t,J=2.1Hz,1H),7.01(ddd,J=8.0,2.5,1.2Hz,1H),5.21(tt,J=5.6,2.6Hz,1H ),4.91(s,2H),4.19(q,J=7.1Hz,2H),2.55–2.46(m,1H),1.96(tt,J=9.2,4.6Hz,2 H), 1.91–1.78 (m, 2H), 1.66 (ddt, J = 21.5, 11.0, 3.7Hz, 4H), 1.23 (t, J = 7.1Hz, 3H).

[0771] Example 111: Synthesis of isopropyl 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (Compound 271)

[0772]

[0773] Isopropyl 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate was prepared using the procedure in Example 56. LCMS (ESI) = 490.3 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ12.07(s,1H),7.92(d,J=8.4Hz,1H),7.49–7.33(m,4H),7.28(t,J=2.0Hz,1H),7.00(ddd,J=8.0,2.6,1.2Hz,1H),5.21 (dt,J=5.6,2.9Hz,1H),5.02(hept,J=6.2Hz,1H),4.87(s,2H),2.03–1.89(m,2H),1.89–1.78(m,2H),1.76–1.55(m,2H),1.23(d,J=6.3Hz,6H).

[0774] Example 112: Synthesis of 2-((3'-ethoxy-4-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 272)

[0775]

[0776] 2-((3'-ethoxy-4-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid was prepared from 5-bromo-2-methylphenol and ethyl 2-bromobutyrate using the procedures in Examples 42 and 9. LCMS (ESI) = 450.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.91 (d, J = 8.4Hz, 1H), 7.36–7.19 (m, 4H), 7.10 (s, 1H), 4.84 (s, 1H), 4. 34–4.20(m,2H),2.25(s,3H),2.03–1.84(m,2H),1.40(t,J=6.9Hz,3H),1.06(t,J=7.4Hz,3H).

[0777] Example 113: Synthesis of 5-(3-(cyclopentyloxy)-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 273)

[0778]

[0779] 3'-(Cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carbonitrile was prepared from 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile using the procedure in Example 6. Into an 8-mL vial was placed 3'-(cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carbonitrile (139 mg, 0.268 mmol, 1.00 equiv) in DMF (1.0 mL) and toluene (1.0 mL). Triethylamine hydrochloride (92.2 mg, 0.670 mmol, 2.50 equiv) and sodium azide (43.6 mg, 0.670 mmol, 2.50 equiv) were added, and the resulting solution was stirred at 110° C. for 17 hr. The reaction was quenched by adding 5 mL of water, and the pH of the solution was adjusted to 6 with 1 M HCl. The solid was collected by filtration and dried under a heat lamp to give 50 mg (33%) of 5-(3-(cyclopentyloxy)-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one as a gray solid. LCMS (ESI) = 562.3 [M+H] + .

[0780] 5-(3-(Cyclopentyloxy)-4'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure in Example 6. LCMS (ESI) = 442.2 [M+H] + . 1 HNMR(300MHz,DMSO-d6)δ12.00(s,1H),8.13(d,J=8.4Hz,2H),7.98(d,J=8.4Hz,1H),8.13(d,J=8.7Hz, 2H),7.49(d,J=7.8Hz,2H),5.25–5.23(m,1H),2.02–1.97(m,2H),1.93–1.84(m,2H),1.79–1.65(m,4H).

[0781] Example 114: Synthesis of (S)-2-amino-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)propanoic acid (Compound 274)

[0782]

[0783] (S)-2-Amino-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)propanoic acid was prepared from (S)-3-(3-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid and 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one using a similar procedure as described in the previous example. LCMS (ESI) = 421.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6) δ7.99(d,J=8.4Hz,1H),7.70–7.59(m,2H),7.48–7.37(m,3H),7.33(s,1H),4.32(d,J=7.1Hz,2H),1.43(t,J=6.8Hz,3H).

[0784] Example 115: Synthesis of (R)-2-amino-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)propanoic acid (Compound 275)

[0785]

[0786] (R)-2-Amino-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)propanoic acid was prepared from (R)-3-(3-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid and 5-(...

Claims

1. A compound having the structure of formula (I"): in: R 1 is a phenyl group substituted with CH2- by C(O)OH; CN; B(OH)2; C(O)OH; NH-C(O)-C 1-6 Straight or branched alkyl; NH2; C(O)NH2; C(O)NH-C 3-8 Cycloalkyl; C(O)NH-phenyl; C(O)-N(C 1-6 Straight-chain or branched alkyl)(phenyl); C(O)NH-unsubstituted C 2-9 Heteroaryl; C 1-6 Straight or branched alkyl-OH; NH-C substituted by C(O)OH 1-6 Straight or branched alkyl; C(O)NH-substituted by C(O)OH 1-6 Straight or branched alkyl; CH2C(O)OH; C(O)N(R 10 )2 or N(R 10 ) 2, Two of the R 10 Together with the nitrogen atom to which they are attached, they form a 5- or 6-membered heterocycloalkyl ring optionally substituted by one, two or three groups independently selected from oxo and C(O)OH; C(O)NHS(O)2N(C 1-6 Straight chain or branched chain alkyl)2; C 3-8 Cycloalkyl; or optionally one, two or three R 8 A 5- or 6-membered heteroaryl group substituted by a group, wherein the heteroaryl group refers to an aryl group including one or more ring heteroatoms selected from nitrogen, oxygen and sulfur; R 2 H, OH, OC 1-6 Straight or branched alkyl or OC 3-6 Cyclic alkyl; Each R 3 Independently selected from OC 1-6 Straight or branched alkyl, SC 1-6 Straight-chain or branched alkyl, NH2 or NO2; Each R 5 independently selected from halogen; OH; O-C(O)OC 1-6 Straight or branched alkyl or C(O)OH substituted C 1-6 Straight or branched alkyl; O-C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 3-6 Cyclic alkyl; C(O)N(R 10 )2, where two R 10 Together with the nitrogen atom to which they are attached, they form a 5- or 6-membered heterocycloalkyl ring; C(O)OC 1-6 Straight or branched alkyl; C(O)OH; NH2; C(O)NH2; C 1-9 Heteroaryl, wherein the heteroaryl refers to an aryl group including one or more ring heteroatoms selected from nitrogen, oxygen and sulfur; C 1-6 Straight or branched chain alkyl; OC 1-6 Straight or branched alkyl; NH-C(O)-C 1-6 Straight or branched alkyl; NH- is replaced by C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 1-6 Straight or branched alkyl; O- is C 1-6 Straight-chain or branched alkoxy-substituted (C 1-6 Straight chain or branched alkyl-phenyl); NH-C 1-6 Straight or branched chain alkyl; C 1-6 Straight or branched alkyl-C(O)OH; C 3-6 Cyclic alkyl-C(O)OH; C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched chain alkyl; C 3-6 Cyclic alkyl-C(O)OC 1-6 Straight or branched alkyl; O-substituted by C(O)OH (C 1-6 Straight chain or branched alkyl-phenyl); C 1-6 Straight or branched alkyl- is selected from NH2, OH, C(O)OH, C(O)OC 1-6 Straight or branched alkyl or NH-C(O)-C 1-6 One or two substituents of a linear or branched alkyl group substituted with C 1-6 Straight or branched chain alkyl; C 2-6 Alkenyl-C(O)OH; OC 1-6 Straight or branched chain alkyl; OC 1-6 Straight or branched alkyl-C 2-9 Heterocycloalkyl; or O-NH-C 1-6 Straight chain or branched chain alkyl or N(C 1-6 Straight chain or branched alkyl)2 substituted C 1-6 Straight or branched chain alkyl; Each R 8 Independently selected from C(O)OH, C(O)OC 1-6 Straight or branched alkyl, C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched alkyl, C 1-6 Straight or branched alkyl -C(O)OH or C 1-6 Straight or branched chain alkyl; Each R 13 Independently selected from C 1-6 Straight or branched chain alkyl; m is 1, 2, 3 or 4; n is 0 or 1; and p is 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof.

2. A compound having the structure of formula (I'): in: R 1 is a phenyl group substituted with CH2- by C(O)OH; CN; B(OH)2; C(O)OH; NH-C(O)-C 1-6 Straight or branched alkyl; NH2; C(O)NH2; C(O)NH-C 3-8 Cycloalkyl; C(O)NH-phenyl; C(O)-N(C 1-6 Straight-chain or branched alkyl)(phenyl); C(O)NH-unsubstituted C 2-9 Heteroaryl; C 1-6 Straight or branched alkyl-OH; NH-C substituted by C(O)OH 1-6 Straight or branched alkyl; C(O)NH-substituted by C(O)OH 1-6 Straight or branched chain alkyl; CH2C(O)OH;C(O)N(R 10 )2 or N(R 10 ) 2, Two of the R 10 Combined with the nitrogen atom to which they are attached, they form a group optionally substituted by one, two or three independently selected from oxo and C(O)OH substituted 5- or 6-membered heterocycloalkyl ring; C(O)NHS(O)2N(C 1-6 Straight chain or branched chain alkyl)2; C 3-8 Cycloalkyl; or optionally one, two or three R 8 A 5- or 6-membered heteroaryl group substituted by a group, wherein the heteroaryl group refers to an aryl group including one or more ring heteroatoms selected from nitrogen, oxygen and sulfur; R 2 H, OH, OC 1-6 Straight or branched alkyl or OC 3-6 Cyclic alkyl; Each R 3 Independently selected from OC 1-6 Straight or branched alkyl, SC 1-6 Straight chain or branched chain alkyl or NH2; Each R 5 independently selected from halogen; OH; O-C(O)OC 1-6 Straight or branched alkyl or C(O)OH substituted C 1-6 Straight or branched alkyl; O-C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 3-6 Cyclic alkyl; C(O)N(R 10 )2, where two R 10 Together with the nitrogen atom to which they are attached, they form a 5- or 6-membered heterocycloalkyl ring; C(O)OC 1-6 Straight or branched alkyl; C(O)OH; NH2; C(O)NH2; C 1-9 heteroaryl, wherein the heteroaryl group refers to an aryl group including one or more ring heteroatoms selected from nitrogen, oxygen and sulfur; C 1-6 Straight or branched chain alkyl; OC 1-6 Straight or branched alkyl; NH-C(O)-C 1-6 Straight or branched alkyl; NH- is replaced by C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 1-6 Straight or branched alkyl; O- is C 1-6 Straight-chain or branched alkoxy-substituted (C 1-6 Straight chain or branched alkyl-phenyl); NH-C 1-6 Straight or branched chain alkyl; C 1-6 Straight or branched alkyl-C(O)OH; C 3-6 Cyclic alkyl-C(O)OH; C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched chain alkyl; C 3-6 Cyclic alkyl-C(O)OC 1-6 Straight or branched alkyl; O-substituted by C(O)OH (C 1-6 Straight chain or branched alkyl-phenyl); C 1-6 Straight or branched alkyl- is selected from NH2, OH, C(O)OH, C(O)OC 1-6 Straight or branched alkyl or NH-C(O)-C 1-6 One or two substituents of a linear or branched alkyl group substituted with C 1-6 Straight or branched chain alkyl; C 2-6 Alkenyl-C(O)OH; OC 1-6 Straight or branched alkyl; or O- is replaced by NHC 1-6 Straight chain or branched chain alkyl or N(C 1-6 Straight chain or branched alkyl)2 substituted C 1-6 Straight or branched chain alkyl; Each R 8 Independently selected from C(O)OH, C(O)OC 1-6 Straight or branched alkyl, C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched alkyl, C 1-6 Straight or branched alkyl -C(O)OH or C 1-6 Straight or branched chain alkyl; n is 0 or 1; and p is 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof.

3. A compound having the structure of formula (I): in: R 1 is a phenyl group substituted with CH2- by C(O)OH; CN; B(OH)2; C(O)OH; NH-C(O)-C 1-6 Straight or branched alkyl; NH2; C(O)NH2; C(O)NH-C 3-8 Cycloalkyl; C(O)NH-phenyl; C(O)-N(C 1-6 Straight-chain or branched alkyl)(phenyl); C(O)NH-unsubstituted C 2-9 Heteroaryl; C 1-6 Straight or branched alkyl-OH; NH-C substituted by C(O)OH 1-6 Straight or branched alkyl; C(O)NH-substituted by C(O)OH 1-6 Straight or branched alkyl; CH2C(O)OH; C(O)N(R 10 )2 or N(R 10 ) 2, Two of the R 10 Together with the nitrogen atom to which they are attached, they form a 5- or 6-membered heterocycloalkyl ring optionally substituted by one, two or three groups independently selected from oxo and C(O)OH; C(O)NHS(O)2N(C 1-6 Straight chain or branched chain alkyl)2; C 3-8 Cycloalkyl; or optionally one, two or three R 8 A 5- or 6-membered heteroaryl group substituted by a group, wherein the heteroaryl group refers to an aryl group including one or more ring heteroatoms selected from nitrogen, oxygen and sulfur; R 2 H, OH, OC 1-6 Straight or branched alkyl or OC 3-6 Cyclic alkyl; Each R 3 Independently selected from OC 1-6 Straight or branched alkyl, SC 1-6 Straight chain or branched chain alkyl or NH2; Each R 5 independently selected from halogen; OH; O-C(O)OC 1-6 Straight or branched alkyl or C(O)OH substituted C 1-6 Straight or branched alkyl; O-C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 3-6 Cyclic alkyl; C(O)N(R 10 )2, where two R 10 Together with the nitrogen atom to which they are attached, they form a 5- or 6-membered heterocycloalkyl ring; C(O)OC 1-6 Straight or branched alkyl; C(O)OH; NH2; C(O)NH2; C 1-9 Heteroaryl, wherein the heteroaryl refers to an aryl group including one or more ring heteroatoms selected from nitrogen, oxygen and sulfur; C 1-6 Straight or branched chain alkyl; OC 1-6 Straight or branched alkyl; NH-C(O)-C 1-6 Straight or branched alkyl; NH- is replaced by C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 1-6 Straight or branched alkyl; O- is C 1-6 Straight-chain or branched alkoxy-substituted (C 1-6 Straight chain or branched alkyl-phenyl); NH-C 1-6 Straight or branched alkyl; O-substituted by C(O)OH (C 1-6 Straight chain or branched alkyl-phenyl); OC 1-6 Straight or branched chain alkyl; OC 1-6 Straight or branched alkyl-C 2-9 Heterocycloalkyl; or O-NHC 1-6 Straight chain or branched chain alkyl or N(C 1-6 Straight chain or branched alkyl)2 substituted C 1-6 Straight or branched chain alkyl; Each R 8 Independently selected from C(O)OH, C(O)OC 1-6 Straight or branched alkyl, C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched alkyl, C 1-6 Straight or branched alkyl -C(O)OH or C 1-6 Straight or branched chain alkyl; n is 0 or 1; and p is 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 1 for 5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein p is 0, 1 or 2.

6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein each R 5 independently selected from halogen; OH; O-C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 1-6 Straight or branched alkyl; O-C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 3-6 Cyclic alkyl; C(O)N(R 10 )2, where two R 10 Together with the nitrogen atom to which they are attached, they form a 5- or 6-membered heterocycloalkyl ring; C(O)OC 1-6 Straight or branched alkyl; C(O)OH; NH2; C(O)NH2; C 1-9 Heteroaryl; C 1-6 Straight or branched chain alkyl; OC 1-6 Straight or branched alkyl; NH-C(O)-C 1-6 Straight or branched alkyl; NH- is replaced by C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 1-6 Straight or branched alkyl; O- is C 1-6 Straight-chain or branched alkoxy-substituted (C 1-6 Straight chain or branched alkyl-phenyl); NH-C 1-6 Straight or branched chain alkyl; C 1-6 Straight or branched alkyl-C(O)OH; C 3-6 Cyclic alkyl-C(O)OH; C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched chain alkyl; C 3-6 Cyclic alkyl-C(O)OC 1-6 Straight or branched alkyl; O-substituted by C(O)OH (C1-6 Straight chain or branched alkyl-phenyl); C 1-6 Straight or branched alkyl- is selected from NH2, OH, C(O)OH, C(O)OC 1-6 Straight or branched alkyl or NH-C(O)-C 1-6 One or two substituents of a linear or branched alkyl group substituted with C 1-6 Straight or branched chain alkyl; OC 1-6 Straight or branched alkyl; or O- is replaced by NHC 1-6 Straight chain or branched chain alkyl or N(C 1-6 Straight chain or branched alkyl)2 substituted C 1-6 Straight chain or branched chain alkyl.

7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein each R 5 independently selected from halogen; OH; O-C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 1-6 Straight or branched alkyl; O-C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 3-6 Cyclic alkyl; C(O)N(R 10 )2, where two R 10 Together with the nitrogen atom to which they are attached, they form a 5- or 6-membered heterocycloalkyl ring; C(O)OC 1-6 Straight or branched alkyl; C(O)OH; NH2; C(O)NH2; C 1-9 Heteroaryl; C 1-6 Straight or branched chain alkyl; OC 1-6 Straight or branched alkyl; NH-C(O)-C 1-6 Straight or branched alkyl; NH- is replaced by C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 1-6 Straight or branched alkyl; O- is C 1-6 Straight-chain or branched alkoxy-substituted (C 1-6 Straight chain or branched alkyl-phenyl); NH-C 1-6 Straight or branched chain alkyl; C 1-6 Straight or branched alkyl-C(O)OH; C 3-6 Cyclic alkyl-C(O)OH; C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched chain alkyl; C 3-6 Cyclic alkyl-C(O)OC 1-6 Straight or branched alkyl; O-substituted by C(O)OH (C 1-6 Straight chain or branched alkyl-phenyl); OC 1-6Straight or branched alkyl; or O- is replaced by NHC 1-6 Straight chain or branched chain alkyl or N(C 1-6 Straight chain or branched alkyl)2 substituted C 1-6 Straight chain or branched chain alkyl.

8. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein each R 5 independently selected from OH; O- is C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 1-6 Straight or branched alkyl; O-C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 3-6 Cyclic alkyl; C(O)N(R 10 )2, where two R 10 Together with the nitrogen atom to which they are attached, they form a 5- or 6-membered heterocycloalkyl ring; C(O)OC 1-6 Straight or branched alkyl; C(O)OH; C(O)NH2; C 1-6 Straight or branched chain alkyl; OC 1-6 Straight or branched alkyl; O- is C 1-6 Straight-chain or branched alkoxy-substituted (C 1-6 Straight chain or branched alkyl-phenyl); C 1-6 Straight or branched alkyl-C(O)OH; C 3-6 Cyclic alkyl-C(O)OH; C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched chain alkyl; C 3-6 Cyclic alkyl-C(O)OC 1-6 Straight or branched alkyl; O-substituted by C(O)OH (C 1-6 Straight chain or branched alkyl-phenyl); OC 1-6 Straight or branched alkyl; O- is NHC 1-6 Straight chain or branched chain alkyl or N(C 1-6 Straight chain or branched alkyl)2 substituted C 1-6 Straight or branched chain alkyl; and 9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein each R 5 Independently selected from C(O)OC 1-6 Straight-chain or branched alkyl and C(O)OH.

10. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein each R 5 independently selected from OH; O- is C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 1-6Straight or branched alkyl; O-C(O)OC 1-6 Straight chain or branched alkyl or C(O)OH substituted 3-6 Cyclic alkyl; OC 1-6 Straight or branched alkyl; O- is C 1-6 Straight-chain or branched alkoxy-substituted (C 1-6 Straight chain or branched alkyl-phenyl); C 1-6 Straight or branched alkyl-C(O)OH; C 3-6 Cyclic alkyl-C(O)OH; C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched chain alkyl; C 3-6 Cyclic alkyl-C(O)OC 1-6 Straight or branched alkyl; O-substituted by C(O)OH (C 1-6 Straight chain or branched alkyl-phenyl); OC 1-6 Straight or branched alkyl; or O- is replaced by NHC 1-6 Straight chain or branched chain alkyl or N(C 1-6 Straight chain or branched alkyl)2 substituted C 1-6 Straight chain or branched chain alkyl.

11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R 5 C 1-6 Straight or branched alkyl-C(O)OH; C 3-6 Cyclic alkyl-C(O)OH; C 1-6 Straight or branched alkyl-C(O)OC 1-6 Straight or branched chain alkyl or C 3-6 Cyclic alkyl-C(O)OC 1-6 Straight chain or branched chain alkyl.

12. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R 5 C 1-6 Straight or branched alkyl -C(O)OH or C 3-6 Cyclic alkyl-C(O)OH.

13. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2.

14. The compound according to claim 13, or a pharmaceutically acceptable salt thereof, wherein p is 1.

15. The compound according to claim 13, or a pharmaceutically acceptable salt thereof, wherein p is 2.

16. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein p is 0.

17. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally replaced by one, two or three R 8 A 5- or 6-membered heteroaryl group substituted by a group.

18. The compound according to claim 17, or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally replaced by one, two or three R 8 A 5-membered heteroaryl group substituted by a group.

19. The compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally replaced by one, two or three R 8 A 5-membered heteroaryl substituted by a radical, wherein the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl and thiadiazolyl.

20. The compound according to claim 19, or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally replaced by one or two R 8 A 5-membered heteroaryl substituted by a radical, wherein the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl and isoxazolyl.

21. The compound according to claim 17, or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally replaced by one, two or three R 8 A 6-membered heteroaryl group substituted by a group.

22. The compound according to claim 21, or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally replaced by one, two or three R 8 A 6-membered heteroaryl substituted by a group, wherein the 6-membered heteroaryl is selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl and triazinyl.

23. The compound according to claim 21 or 22, or a pharmaceutically acceptable salt thereof, wherein R 1 is optionally replaced by one or two R 8 A 6-membered heteroaryl substituted by a group, wherein the 6-membered heteroaryl is selected from pyridyl and pyrimidinyl.

24. The compound according to claim 23, or a pharmaceutically acceptable salt thereof, wherein each R 8 Independently selected from C(O)OH, C(O)OC 1-6 Straight or branched alkyl, C 1-6 Straight or branched alkyl -C(O)OH and C 1-6 Straight chain or branched chain alkyl.

25. The compound according to claim 24, or a pharmaceutically acceptable salt thereof, wherein each R 8 Independently selected from C(O)OH and C(O)OC 1-6 Straight chain or branched chain alkyl.

26. The compound according to claim 19, or a pharmaceutically acceptable salt thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl group selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl and isoxazolyl.

27. The compound according to claim 23, or a pharmaceutically acceptable salt thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl group selected from pyridyl and pyrimidinyl.

28. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 1 C(O)NH2; C(O)NH-C 3-8 Cycloalkyl; C(O)NH-phenyl; C(O)-N(C 1-6 Straight-chain or branched alkyl)(phenyl); C(O)NH-unsubstituted C 2-9 Heteroaryl; C(O)NH-substituted by C(O)OH 1-6 Straight or branched alkyl; or C(O)N(R 10 ) 2, Two of the R 10 Together with the nitrogen atom to which they are attached they form a 5 or 6 membered heterocycloalkyl ring optionally substituted with one, two or three groups independently selected from oxo and C(O)OH.

29. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 1 NH-C(O)-C 1-6 Straight or branched alkyl; NH2; or NH-substituted by C(O)OH 1-6 Straight chain or branched chain alkyl.

30. The compound according to claim 29, or a pharmaceutically acceptable salt thereof, wherein R 1 NH2; or NH- is replaced by C(O)OH 1-6 Straight chain or branched chain alkyl.

31. The compound according to claim 30, or a pharmaceutically acceptable salt thereof, wherein R 1 is NH2.

32. The compound according to claim 30, or a pharmaceutically acceptable salt thereof, wherein R 1 C is NH- replaced by C(O)OH 1-6 Straight chain or branched chain alkyl.

33. The compound according to claim 28, or a pharmaceutically acceptable salt thereof, wherein R 1 C(O)N(R 10 ) 2, Two R's 10 Together with the nitrogen atom to which they are attached they form a 5 or 6 membered heterocycloalkyl ring optionally substituted with one, two or three groups independently selected from oxo and -C(O)OH.

34. The compound according to claim 33, or a pharmaceutically acceptable salt thereof, wherein R 1 C(O)N(R 10 ) 2, Two R's 10 Together with the nitrogen atom to which they are attached they form a 5-membered heterocycloalkyl ring substituted with -C(O)OH.

35. The compound according to claim 33, or a pharmaceutically acceptable salt thereof, wherein R 1 C(O)N(R 10 ) 2, Two R's 10 Together with the nitrogen atom to which they are attached they form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

36. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 1 It is C(O)OH.

37. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 1 for 38. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 2 H, OC 1-6 Straight or branched alkyl or OC 3-6 Cyclic alkyl.

39. The compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein R 2 For OC 1-6 Straight or branched alkyl or OC 3-6 Cyclic alkyl.

40. The compound according to claim 39, or a pharmaceutically acceptable salt thereof, wherein R 2 It is OCH2CH3.

41. The compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein R 2 For H.

42. The compound of claim 41, or a pharmaceutically acceptable salt thereof, wherein n is 1.

43. A compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein each R 3 Independently selected from OC 1-6 Straight chain or branched chain alkyl or NH2.

44. The compound according to claim 43, or a pharmaceutically acceptable salt thereof, wherein each R 3 For OC 1-6 Straight chain or branched chain alkyl.

45. The compound according to claim 44, or a pharmaceutically acceptable salt thereof, wherein each R 3 It is O-methyl.

46. ​​The compound of claim 41, or a pharmaceutically acceptable salt thereof, wherein n is 0.

47. A compound selected from: or a pharmaceutically acceptable salt thereof.

48. A compound selected from: or a pharmaceutically acceptable salt thereof.

49. A compound selected from: or a pharmaceutically acceptable salt thereof.

50. A compound selected from: or a pharmaceutically acceptable salt thereof.

51. A pharmaceutical composition comprising a compound according to any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.